About The Drug Estradiol Transdermal System aka Alora
![ClusterMed ClusterMed](/images/clustermed.jpg)
Find Estradiol Transdermal System side effects, uses, warnings, interactions and indications. Estradiol Transdermal System is also known as Alora.
Estradiol Transdermal System
![Estradiol Transdermal System Prescription Drug Bottle Estradiol Transdermal System Prescription Drug Bottle](/images/prescriptiondrugbottle.jpg)
About Estradiol Transdermal System aka Alora |
---|
What's The Definition Of The Medical Condition Estradiol Transdermal System?Clinical Pharmacology CLINICAL PHARMACOLOGY Mechanism of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics.
Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.
The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle.
After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues.
Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.
Estrogens act through binding to nuclear receptors in estrogen-responsive tissues.
To date, two estrogen receptors have been identified.
These vary in proportion from tissue to tissue.
Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism.
Estrogens act to reduce the elevated concentrations of these hormones seen in postmenopausal women.
Pharmacodynamics There are no pharmacodynamic data for MINIVELLE.
Pharmacokinetics Absorption In a single-dose, two way-crossover clinical study conducted in 96 healthy, non-smoking postmenopausal women under fed condition, MINIVELLE (0.1 mg per day) was bioequivalent to Vivelle (0.1 mg per day) based on estradiol exposure (AUC0-84) and estradiol peak concentration (Cmax) following a single-dose on the lower abdomen for 84 hours.
Estradiol pharmacokinetics were characterized in a separate open-label, single-center, randomized, singledose, three-way crossover study conducted in 36 healthy, non-smoking postmenopausal women (aged 40 to 65 years).
MINIVELLE delivering nominal estradiol of approximately 0.025 mg, 0.05 mg, and 0.1 mg per day were applied to the lower abdomen under fed state in a crossover fashion for 84 hours.
The mean estradiol pharmacokinetics parameters are summarized in Table 2.
AUC and Cmax are dose proportional from 0.025 mg to 0.1 mg per day.
Table 2: Mean (SD) Serum Pharmacokinetic Parameters of Baseline-Uncorrected Estradiol following a Single Dose of MINIVELLE (N=36) Parameter 0.1 mg/day 0.05 mg/day 0.025 mg/day AUC84 (pg•hr/mL) 5875 (1857) 3057 (980) 1763 (600) AUC120 (pg•hr/mL) 6252 (1938) 3320 (1038) 1979 (648) Cmax (pg/mL) 117 (39.3) 56.6 (17.6) 30.3 (11.1) Tmax (hr)a 24.0 (8-60) 24.0 (8-60) 36.0 (8-84) a Median (minimum-maximum) Figure 1 illustrates the mean baseline-uncorrected estradiol serum concentrations of MINIVELLE at three different strengths.
Figure 1: Mean Baseline-Uncorrected Estradiol Serum Concentration-Time Profiles Following a Single Dose of MINIVELLE 0.1 mg per day (Treatment A), 0.05 mg per day (Treatment B), and 0.025 mg per day (Treatment C) (N=36) Distribution The distribution of exogenous estrogens is similar to that of endogenous estrogens.
Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs.
Estrogens circulate in the blood largely bound to SHBG and albumin.
Metabolism Exogenous estrogens are metabolized in the same manner as endogenous estrogens.
Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions.
These transformations take place mainly in the liver.
Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite.
Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption.
In postmenopausal women a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.
Excretion Estradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates.
The mean half-life values of estradiol calculated from treatment groups in the bioequivalence study and doseproportionality study after dosing with the MINIVELLE ranged from 6.2 to 7.9 hours.
After removal of the transdermal systems, serum concentrations of estradiol and estrone returned to baseline concentrations within 24 hours.
Use in Specific Populations No pharmacokinetic studies were conducted with MINIVELLE in specific populations, including patients with renal or hepatic impairment.
Adhesion and Adhesive Residue Based on combined data from bioequivalence and dose proportionality studies consisting of 208 MINIVELLE observations, approximately 98 percent of the observations had an adhesion score of 0 (i.e., the skin adhesion rate was greater than or equal to 90 percent) over the 84-hour wear period.
One subject had a complete detachment during the wear period.
Approximately 65 percent of the transdermal systems evaluated in these studies were with MINIVELLE 0.1 mg per day (6.6 cm² active surface area).
After removal of MINIVELLE, subjects had either no adhesive residue (score of 0) or light adhesive residue (score of 1).
There were no subjects who had medium adhesive residue.
Of the 208 MINIVELLE observations, 54 percent had light adhesive residue and 46 percent had no adhesive residue.
Clinical Studies Effects on Vasomotor Symptoms There have been no efficacy and safety trials conducted with MINIVELLE.
In a pharmacokinetic study, MINIVELLE was shown to be bioequivalent to Vivelle.
In two controlled clinical trials with Vivelle, in a total of 356 subjects, the 0.075 and 0.1 mg doses were superior to placebo in relieving vasomotor symptoms at Weeks 4, 8 and 12 of treatment.
In these studies, the 0.0375 and 0.05 mg doses did not differ from placebo at Week 4, therefore, a third 12-week placebocontrolled study in 255 subjects was performed with Vivelle to establish the efficacy of the lowest dose of 0.0375 mg.
The baseline mean daily number of hot flushes in these 255 subjects was 11.5.
Results at Weeks 4, 8, and 12 of treatment are shown in Figure 2.
Figure 2: Mean (SD) change from baseline in mean daily number of hot flushes for Vivelle 0.0375 mg versus Placebo in a 12-week trial.
The 0.0375 mg dose was superior to placebo in reducing both the frequency and severity of vasomotor symptoms at Weeks 4, 8 and 12 of treatment.
Women's Health Initiative Studies The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases.
The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome.
A “global index” included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other cause.
These substudies did not evaluate the effects of CE-alone or CE plus MPA on menopausal symptoms.
WHI Estrogen-Alone Substudy The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints.
Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow- up of 7.1 years are presented in Table 3.
Table 3: Relative and Absolute Risk Seen in the Estrogen Alone Substudy of WHIa Event Relative Risk CE vs.
Placebo (95% nCIb) CE n = 5,310 Placebo n = 5,429 Absolute Risk per 10,000 Women-Years CHD eventsc 0.95 (0.78-1.16) 54 57 Non-fatal MIc 0.91 (0.73-1.14) 40 43 CHD deathc 1.01 (0.71-1.43) 16 16 All strokesc 1.33 (1.15-1.68) 45 33 Ischemic strokec 1.55 (1.19-2.01) 38 25 Deep vein thrombosisc,d 1.47 (1.06-2.06) 23 15 Pulmonary embolismc 1.37 (0.90-2.07) 14 10 Invasive breast cancerc 0.80 (0.62-1.04) 28 34 Colorectal cancere 1.08 (0.75-1.55) 17 16 Hip fracturec 0.65 (0.45-0.94) 12 19 Vertebral fracturesc,d 0.64 (0.44-0.93) 11 18 Lower arm/wrist fracturesc,d 0.58 (0.47-0.72) 35 59 Total fracturesc,d 0.71 (0.64-0.80) 144 197 Death due to other causese,f 1.08 (0.88-1.32) 53 50 Overall mortalityc,d 1.04 (0.88-1.22) 79 75 Global Indexg 1.02 (0.92-1.13) 206 201 a Adapted from numerous WHI publications.
WHI publications can be viewed at www.nhlbi.nih.gov/whi.
b Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.
c Results are based on centrally adjudicated data for an average follow-up of 7.1 years.
d Not included in “global index”.
e Results are based on an average follow-up of 6.8 years.
f All deaths, except from breast or colorectal cancer, definite or probable CHD, PE, or cerebrovascular disease.
g A subset of the events was combined in a “global index”, defined as the earliest occurrence of CHD events.
invasive breast cancer, stroke, PE, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
For those outcomes included in the WHI “global index” that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures.9 The absolute excess risk of events included in the “global index” was a non-significant 5 events per 10,000 women-years.
There was no difference between the groups in terms of all-cause mortality.
No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared to placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years.
Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average followup of 7.1 years, reported no significant differences in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo.
Estrogen-alone increased the risk for ischemic stroke, and this excess risk was present in all subgroups of women examined.10 Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile.
The WHI estrogen-alone substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [hazard ratio (HR) 0.63 (95 percent CI, 0.36- 1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46-1.11)].
WHI Estrogen Plus Progestin Substudy The WHI estrogen plus progestin substudy was stopped early.
According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the “global index”.
The absolute excess risk of events included in the “global index” was 19 per 10,000 women-years.
For those outcomes included in the WHI “global index” that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reduction per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures.
Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 4.
These results reflect centrally adjudicated data after an average follow-up of 5.6 years.
Table 4: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Yearsa,b Event Relative Risk CE/MPA vs.
Placebo (95% nCIc) CE/MPA (n = 8,506) Placebo (n = 8, 1026) Absolute Risk per 10,000 Women-Years CHD events 1.23 (0.99-1.53) 41 34 Non-fatal MI 1.28 (1.00-1.63) 31 25 CHD death 1.10 (0.70-1.75) 8 8 All strokes 1.31 (1.03-1.68) 33 25 Ischemic stroke 1.44 (1.09-1.90) 26 18 Deep vein thrombosisd 1.95 (1.43-2.67) 26 13 Pulmonary embolism 2.13 (1.45-3.11) 18 8 Invasive breast cancere 1.24 (1.01-1.54) 41 33 Colorectal cancer 0.61 (0.42-0.87) 10 16 Endometrial cancerd 0.81 (0.48-1.36) 6 7 Cervical cancerd 1.44 (0.47-4.42) 2 1 Hip fracture 0.67 (0.47-0.96) 11 16 Vertebral fracturesd 0.65 (0.46-0.92) 11 17 Lower arm/wrist fracturesd 0.71 (0.59-0.85) 44 62 Total fracturesd 0.76 (0.69-0.83) 152 199 Overall mortalityf 1.00 (0.83-1.19) 52 52 Global Indexg 1.13 (1.02-1.25) 184 165 a Adapted from numerous WHI publications.
WHI publications can be viewed at www.nhlbi.nih.gov/whi.
b Results are based on centrally adjudicated data.
c Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.
d Not included in “global index”.
e Includes metastatic and non-metastatic breast cancer, with the exception of in situ breast cancer.
f All deaths, except from breast or colorectal cancer, definite or probable CHD, PE, or cerebrovascular disease.
g A subset of the events was combined in a “global index”, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile.
The WHI estrogen plus progestin substudy stratified for age showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality [HR 0.69 (95 percent CI, 0.44-1.07)].
Women's Health Initiative Memory Study The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age, 36 percent were 70 to 74 years of age, and 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo.
After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66).
The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years.
Probable dementia as defined in this study included Alzheimer's disease (AD), vascular dementia (VaD) and mixed type (having features of both AD and VaD).
The most common classification of probable dementia in the treatment group and the placebo group was AD.
Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
The WHIMS estrogen plus progestin ancillary study enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, and 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo.
After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21- 3.48).
The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 per 10,000 women-years.
Probable dementia as defined in this study included AD, VaD and mixed type (having features of both AD and VaD).
The most common classification of probable dementia in the treatment group and the placebo group was AD.
Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, and Use in Specific Populations].
When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60).
Differences between groups became apparent in the first year of treatment.
It is unknown whether these findings apply to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, and Use in Specific Populations.
REFERENCES 9.
Jackson RD, et al.
Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial.
J Bone Miner Res.
2006;21:817-828.
10.
Hendrix SL, et al.
Effects of Conjugated Equine Estrogen on Stroke in the Women's Health Initiative.
Circulation.
2006;113:2425-2434.
Clinical Pharmacology CLINICAL PHARMACOLOGY Mechanism Of Action Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics.
Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.
The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle.
After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues.
Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.
Estrogens act through binding to nuclear receptors in estrogen-responsive tissues.
To date, two estrogen receptors have been identified.
These vary in proportion from tissue to tissue.
Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism.
Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.
Pharmacodynamics There are no pharmacodynamic data for Menostar.
Pharmacokinetics Absorption The bioavailability of estradiol following application of a Menostar transdermal system, relative to that of a transdermal system delivering 25 mcg per day, was investigated in 18 healthy postmenopausal women, mean age 66 years (range 60 to 80 years).
The mean serum estradiol concentrations upon administration of the two patches to the lower abdomen are shown in Figure 1.
Transdermal administration of Menostar produced geometric mean serum concentration (Cavg) of estradiol of 13.7pg/mL.
No patches failed to adhere during the one week application period of both transdermal systems.
Following application of the Menostar transdermal system to the abdomen, it is estimated to provide an average nominal in-vivo daily delivery of 14 mcg estradiol per day.
The Menostar transdermal delivery system continuously releases estradiol which is transported across intact skin leading to sustained circulating levels of estradiol during a 7-day treatment period.
The systemic availability of estradiol after transdermal administration is about 20 times higher than that after oral administration.
This difference is due to the absence of first pass metabolism when estradiol is given by the transdermal route.
Figure 1: Mean Uncorrected Serum 17ß-Estradiol Concentrations vs.
Time Profile Following Application of the Menostar Transdermal System and the Climara® 6.5 cm² Transdermal System Table 2 provides a summary of estradiol pharmacokinetic parameters determined during evaluation of the Menostar transdermal system using baseline uncorrected serum concentrations.
Summary of Estradiol Pharmacokinetic Parameters (Abdomen Application) Table 2: Summary of Estradiol Pharmacokinetic Parameters (Abdomen Application) Product Estradiol Daily Delivery Rate, mcg/day AUC (0-tlast) pg•h/mL Cmax pg/mL Cavg pg/mL Tmax h Cmin pg/mL Menostar 14 2296 20.6 13.7 42 12.6 Climara 6.5 cm² 25 4151 37.2 24.7 42 20.4 Pharmacokinetic parameters are expressed in geometric means except for the Tmax which represents the median estimate and the Cmin which is expressed as the arithmetic mean.
The estimated estradiol daily delivery rate for Climara 6.5 cm² is quoted from the Climara labeling.
Distribution The distribution of exogenous estrogens is similar to that of endogenous estrogens.
Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs.
Estrogens circulate in the blood largely bound to SHBG and albumin.
In the clinical study with 208 patients on Menostar, SHBG concentration (mean ± SD) remained essentially unchanged over the 2 year period (baseline 45.1 ± 20.1 nmol/L, 24-month visit 46.4 ± 20.9 nmol/L).
Metabolism Exogenous estrogens are metabolized in the same manner as endogenous estrogens.
Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions.
These transformations take place mainly in the liver.
Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite.
Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption.
In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.
Excretion Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.
Adhesion In a Menostar transdermal system pharmacokinetic study with 18 postmenopausal women, no patches failed to adhere during the one week application period Clinical Studies Effects On Bone Mineral Density The efficacy of Menostar in the prevention of postmenopausal osteoporosis was investigated in a 2- year double blind, placebo-controlled, multicenter study in the United States.
A total of 417 postmenopausal women, 60 to 80 years of age, with an intact uterus were enrolled in the study.
All patients received supplemental calcium and vitamin D.
At lumbar spine Menostar increased BMD by 2.3 percent after 1 year and 3 percent after 2 years compared with a 0.5 percent increase after 1 and 2 years of treatment with placebo.
At the hip Menostar increased BMD by 0.9 percent after one year and 0.84 percent after two years compared with a mean decrease of 0.22 percent after 1 year and 0.71 percent after 2 years of placebo treatment.
The changes in BMD from baseline were statistically significantly (p < 0.001) greater during treatment with Menostar than during treatment with placebo for both the spine and hip after 1 and 2 years (Table 3).
Table 3: Mean Percent BMD Change from Baseline in Lumbar Spine and Total Hip (Full Analysis Set) Lumbar spine Total hip Time points Menostar N* = 208 Placebo N = 209 p-value Time points Menostar N = 208 Placebo N = 209 p-value 12-month Endpoint n† = 189 +2.29 n = 186 +0.51 < 0.001 12-month Endpoint n = 189 +0.90 n =184 -0.22 < 0.001 24-month Endpoint n = 189 +2.99 n = 186 +0.54 < 0.001 24-month Endpoint n = 189 +0.84 n = 185 -0.71 < 0.001 *N = total number of patients †n = number of patients with data available for each variable.
The BMD data of the study were analyzed according to baseline estradiol levels of the patients.
Overall, estimated treatment effects on lumbar spine and total hip BMD after 2 years were approximately twice as large in the subgroup with baseline estradiol levels < 5 pg/mL than in the subgroup with baseline estradiol levels ≥ 5 pg/mL (Table 4).
Table 4: Mean Percent Change in Lumbar Spine and Total Hip BMD at 24 months by Subgroups of Baseline Estradiol Level ( < 5 pg/mL, 5 pg/mL) Lumbar spine T otal hip Baseline estradiol levels Menostar Placebo Treatment difference Menostar Placebo Treatment difference < 5 pg/mL n* = 101 n = 97 n = 101 n = 96 +3.50 +0.29 3.21 (p < 0.001) +1.04 -1.09 2.13 (p < 0.001) ≥ 5 pg/mL n = 88 n = 89 n = 88 n = 89 +2.40 +0.81 1.59 (p = 0.002) +0.61 -0.31 0.92 (p = 0.045) * n = number of patients with data available for each variable.
Women's Health Initiative Studies The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases.
The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome.
A “global index” included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other causes.
These substudies did not evaluate the effects of CEalone or CE plus MPA on menopausal symptoms.
WHI Estrogen-Alone Substudy The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risk and benefits of estrogen-alone in predetermined primary endpoints.
Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79: 75.3 percent white, 15.1 percent black, 6.1 percent Hispanic, 3.6 percent Other) after an average follow-up of 7.1 years, are presented in Table 5.
Table 5: Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI Eventb Relative Risk CE vs.
Placebo (95% nCI*) CE n = 5,310 Placebo n = 5,429 Absolute Risk per 10,000 Women-years CHD events† 0.95 (0.78-1.16) 54 57 Non-fatal MI† 0.91 (0.73-1.14) 40 43 CHD death† 1.01 (0.71-1.43) 16 16 All strokes† 1.33 (1.05-1.68) 45 33 Ischemic stroke† 1.55 (1.19-2.01) 38 25 Deep vein thrombosis†,‡ 1.47 (1.06-2.06) 23 15 Pulmonary embolism† 1.37 (0.90-2.07) 14 10 Invasive breast cancer† 0.8 (0.62-1.04) 28 34 Colorectal cancer† 1.08 (0.75-1.55) 17 16 Hip fracture† 0.65 (0.45-0.94) 12 19 Vertebral fractures†,‡ 0.64 (0.44-0.93) 11 18 Lower arm/wrist fractures†,‡ 0.58 (0.47-0.72) 35 59 Total fractures†,‡ 0.71 (0.64-0.80) 144 197 Death due to causes§ ¶ 1.08 (0.88-1.32) 53 50 Overall mortality†,‡ 1.04 (0.88-1.22) 79 75 Global Index# 1.02 (0.92-1.13) 206 201 *Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.
†Results are based on centrally adjudicated data for an average follow-up of 7.1 years.
‡Not included in “global index”.
§Results are based on an average follow-up of 6.8 years.
¶All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.
#A subset of the events was combined in a “global index”, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
For those outcomes included in the WHI “global index” that reached statistical significance, the absolute excess risks per 10,000 women-years in the group treated with CE-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures.9 The absolute excess risk of events included in the “global index” was a non-significant 5 events per 10,000 women years.
There was no difference between the groups in terms of all-cause mortality.
No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years.
See Table 5.
Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in the distribution of stroke subtype and severity, including fatal strokes, in women receiving estrogen-alone compared to placebo.
Estrogenalone increased the risk of ischemic stroke, and this excess risk was present in all subgroups of women examined.10 See Table 5.
Timing of initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile.
The WHI estrogen-alone substudy stratified by age showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [hazard ratio (HR) 0.63 (95 percent CI, 0.36-1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46-1.11)].
WHI Estrogen Plus Progestin Substudy The WHI estrogen plus progestin substudy was stopped early.
According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the “global index”.
The absolute excess risk of events included in the “global index” was 19 per 10,000 women-years.
For those outcomes included in the WHI “global index” that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reduction per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures.
Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.5 percent Black, 5.4 percent Hispanic, 3.9 percent Other), are presented in Table 6.
These results reflect centrally adjudicated data after an average follow-up of 5.6 years.
Table 6: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years Event Relative Risk CE/MPA vs.
placebo (95% nCI*) CE/MPA n = 8,506 Placebo n = 8,102 Absolute Risk per 10,000 Women-years CHD events 1.23 (0.99-1.53) 41 34 Non-fatal MI 1.28 (1.00-1.63) 31 25 CHD death 1.10 (0.70-1.75) 8 8 All strokes 1.31 (1.03-1.68) 33 25 Ischemic stroke 1.44 (1.09-1.90) 26 18 Deep vein thrombosis† 1.95 (1.43-2.67) 26 13 Pulmonary embolism 2.13 (1.45-3.11) 18 8 Invasive breast cancer‡ 1.24 (1.01-1.54) 41 33 Colorectal cancer 0.61 (0.42-0.87) 10 16 Endometrial cancer† 0.81 (0.48-1.36) 6 7 Cervical cancer† 1.44 (0.47-4.42) 2 1 Hip fracture 0.67 (0.47-0.96) 11 16 Vertebral fractures† 0.65 (0.46-0.92) 11 17 Lower arm/wrist fractures† 0.71 (0.59-0.85) 44 62 Total fractures† 0.76 (0.69-0.83) 152 199 Overall mortality§ 1.00 (0.83-1.19) 52 52 Global Index ¶ 1.13 (1.02-1.25) 184 165 *Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.
†Not included in “global index”.
‡Includes metastatic and non-metastatic breast cancer, with the exception of in situ breast cancer.
§All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.
¶A subset of the events was combined in a “global index”, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
Timing of initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile.
The WHI estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age a non-significant trend toward reduced risk for overall mortality [HR 0.69 (95 percent CI 0.44-1.07)].
Women's Health Initiative Memory Study The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo.
After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66).
The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years.
Probable dementia as defined in the study included Alzheimer's disease (AD), vascular dementia (VaD) and mixed types (having features of both AD and VaD).
The most common classification of probable dementia in the treatment group and the placebo group was AD.
Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, and Use in Specific Populations].
The WHIMS estrogen plus progestin ancillary study enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age; 35 percent were 70 to 74 years of age; and 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo.
After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48).
The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years.
Probable dementia as defined in thestudy included AD, VaD and mixed types (having features of both AD and VaD).
The most common classification of probable dementia in the treatment group and the placebo group was AD.
Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, and Use in Specific Populations].
When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60).
Differences between groups became apparent in the first year of treatment.
It is unknown whether these findings apply to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, and Use in Specific Populations] REFERENCES 8.
Shumaker SA, et al.
Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women.
JAMA.
2004;291:2947-2958.
9.
Jackson RD, et al.
Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial.
J Bone Miner Res.
2006;21:817-828.
10.
Hendrix SL, et al.
Effects of Conjugated Equine Estrogen on Stroke in the Women's Health Initiative.
Circulation.
2006;113:2425-2434.
Clinical Pharmacology CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics.
Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.
The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle.
After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues.
Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.
Estrogens act through binding to nuclear receptors in estrogen-responsive tissues.
To date, two estrogen receptors have been identified.
These vary in proportion from tissue to tissue.
Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism.
Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.
Pharmacokinetics The skin metabolizes estradiol only to a small extent.
In contrast, orally administered estradiol is rapidly metabolized by the liver to estrone and its conjugates, giving rise to higher circulating levels of estrone than estradiol.
Therefore, transdermal administration produces therapeutic plasma levels of estradiol with lower levels of estrone and estrone conjugates and requires smaller total doses than does oral therapy.
Absorption Estradiol is transported across intact skin and into the systemic circulation by a passive diffusion process, the rate of diffusion across the stratum corneum being the principal factor.
Alora presents sufficient concentration of estradiol to the surface of the skin to maintain continuous transport over the 3 to 4 day dosing interval.
Direct measurement of total absorbed dose of estradiol through analysis of residual estradiol content of systems worn over a continuous 4-day interval during 251 separate occasions in 123 postmenopausal women demonstrated that the average daily dose absorbed from Alora was 0.003 ± 0.001 mg estradiol per cm2 active surface area.
The nominal mean in vivo daily delivery rates of estradiol calculated from these data are 0.027 mg/day, 0.054 mg/day, 0.081 mg/day, and 0.11 mg/day for the 9 cm2, 18 cm2, 27 cm2, and 36 cm2 Alora, respectively.
In another study, 20 women also were treated with three consecutive doses of Alora 0.05 mg/day, Alora 0.075 mg/day and Alora 0.1 mg/day on abdominal application sites.
Mean steady-state estradiol serum concentrations observed over the dosing interval are shown in Figure 1.
Figure 1: Mean steady-state estradiol serum concentration during the third twice weekly dose of Alora 0.1 mg/day, Alora 0.075 mg/day, and Alora 0.05 mg/day in 20 postmenopausal women.
In a single dose randomized crossover study conducted to compare the effect of site of Alora application, 31 postmenopausal women wore single Alora 0.05 mg/day for 4-day periods on the lower abdomen, upper quadrant of the buttocks, and outside aspect of the hip.
The estradiol serum concentration profiles are shown in Figure 2.
Figure 2: Mean estradiol serum concentrations during a single 4-day wearing of Alora 0.05 mg/day applied by 31 postmenopausal women to the lower abdomen, upper quadrant of the buttocks or outer aspect of the hip.
* Cmax and Cavg statistically different from abdomen Table 1 provides a summary of the estradiol pharmacokinetic parameters studied during biopharmaceutic evaluation of Alora.
Table 1: Mean (SD) Pharmacokinetic Profile of Alora Over an 84-hour Dosing Interval.
Alora (mg/day) Application Site N Dosing Cmax (pg/ml) Cmin (pg/ml) Cavg (pg/ml) CL (L/hr) 0.05 Abdomen 20 Multiple 92 (33) 43 (12) 64 (19) 54 (18) 0.075 Abdomen 20 Multiple 120 (60) 53 (23) 86 (40) 53 (12) 0.1 Abdomen 42 Multiple 144 (57) 58 (20) 98 (38) 61 (18) 0.05 Abdomen 31 Single 53 (23) - 41 (18) 69 (22) Buttock 31 Single 67 (45) - 45 (21) 66 (23) Hip* 31 Single 69 (30) - 48 (17) 62 (18) * Cmax and Cavg statistically different from abdomen Steady-state estradiol serum concentrations were measured in two well-controlled clinical trials in the treatment of menopausal symptoms of 3 month duration (Studies 1 and 2), and one trial in the prevention of postmenopausal osteoporosis of 2 year duration (Study 3).
Table 2 provides a summary of these data.
Table 2: Mean (SD) steady-state estradiol serum concentrations (pg/ml) in clinical trials of 3 month (Studies 1 and 2) and 2 year (Study 3) duration.
Alora (mg/day) Study 1 Study 2 Study 3 0.025 - - 24.5 (12.4) 0.05 46.9 (38.5) 38.8 (38.0) 42.6 (23.7) 0.075 - - 56.7 (36.8) 0.1 99.2 (77.0) 97.0 (87.5) - In a 2-year, randomized, double-blind, placebo-controlled, prevention of postmenopausal osteoporosis study in 355 hysterectomized women, the average baseline-adjusted steady-state estradiol serum concentrations were 18.6 pg/ml (45 patients) for the 0.025 mg/day dose, 35.9 pg/ml (47 patients) for the 0.05 mg/day dose, and 50.1 pg/ml (46 patients) for the 0.075 mg/day dose.
These values were linearly related and dose proportional.
Distribution No specific investigation of the tissue distribution of estradiol absorbed from Alora in humans has been conducted.
The distribution of exogenous estrogens is similar to that of endogenous estrogens.
Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs.
Estrogens circulate in the blood largely bound to sex hormone binding globulin (SHBG) and albumin.
Metabolism Exogenous estrogens are metabolized in the same manner as endogenous estrogens.
Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions.
These transformations take place mainly in the liver.
Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite.
Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption.
In postmenopausal women a significant portion of the circulating estrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.
Excretion Estradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates.
The apparent mean (SD) serum half-life of estradiol determined from biopharmaceutic studies conducted with Alora is 1.75 2.87 hours.
Special Populations Alora has been studied only in healthy postmenopausal women (approximately 90% Caucasian).
There are no long term studies in postmenopausal women with an intact uterus.
No pharmacokinetic studies were conducted in other special populations, including patients with renal or hepatic impairment.
Drug Interactions In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4).
Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism.
Inducers of CYP3A4 such as St.
John’s Wort preparations (Hypericum perforatum), phenobarbital, phenytoin, carbamazepine, rifampin and dexamethasone may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile.
Inhibitors of CYP3A4 such as cimetidine, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.
Adhesion The adhesion potential of Alora was evaluated in a randomized clinical trial involving 408 healthy postmenopausal women who wore placebo systems corresponding to the 18 cm2 size Alora.
The placebos were applied twice weekly for 4 weeks on the lower quadrant of the abdomen.
It should be noted that the lower abdomen, the upper quadrant of the buttocks or outer aspect of the hip are the approved sites of application for Alora.
Subjects were instructed not to do strenuous activities, take baths, use hot tubs or swim.
In 968 observations, there was a partial or complete adhesion rate of approximately 97%.
The total detachment rate was approximately 3%.
Adhesion potentials of the 9 cm2, 27 cm2 and 36 cm2 sizes of Alora have not been studied.
Clinical Studies Effects On Vasomotor Symptoms Efficacy of Alora has been studied in a double blind/double dummy, randomized, parallel group, placebo-controlled trial involving a total of 268 postmenopausal women over a 12-week dosing period.
Only women having estradiol and FSH serum concentrations in the postmenopausal range and who exhibited a weekly average of at least 60 moderate to severe hot flushes during the screening period were enrolled in the studies.
Patients received Alora 0.05 mg/day and a placebo system, or Alora 0.1 mg/day and a placebo system, or two placebo systems dosed twice weekly over a 12-week duration.
Measures of efficacy included mean reduction in weekly number of moderate to severe vasomotor symptoms when compared to the mean baseline average determined during a 2-week pre-dosing screening period.
Alora was shown to be statistically better than placebo at Weeks 4 and 12 for relief of both the frequency (see Table 3) and severity of vasomotor symptoms.
Table 3 Mean Change from Baseline in Frequency of Moderate to Severe Vasomotor Symptoms for Alora Compared to Placebo (ITT).
Week of Therapy Mean Change from Baseline Alora 0.05 mg/day N = 87 Baseline = 90 Alora 0.1 mg/day N = 91 Baseline = 85 Placebo N = 90 Baseline = 92 4* -57 -70 -45 8 -65 -77 -49 12* -68 -79 -54 * Indicates statistically significant differences between both strengths of Alora and placebo using an ANCOVA model adjusting for baseline.
Effects On Vulvar And Vaginal Atrophy Vaginal cytology was obtained pre-dosing and at last visit in 54 women treated with Alora 0.05 mg/day, in 45 women treated with Alora 0.1 mg/day, and in 46 women in the placebo group.
Superficial cells increased by a mean of 18.7%, 23.7%, and 8.7% for the Alora 0.05 mg/day, Alora 0.1 mg/day, and placebo groups, respectively.
Corresponding reductions in basal/parabasal and intermediate cells were also observed.
Effects On Bone Mineral Density Lumbar spine bone mineral density (BMD) was measured by DEXA in a 2-year, randomized, multi-center, double-blind, placebo-controlled study in 355 hysterectomized, non-osteoporotic women (i.e., T-scores > -2.5).
Eighty-six percent of the women were Caucasian, the mean age was 53.2 years (range 26 to 69), and the average number of years since menopause (natural or surgical) was not determined.
Three Alora doses (0.025 mg/day, 0.05 mg/day, and 0.075 mg/day) were compared to placebo in terms of the % change in BMD from baseline to Year 2.
The systems were applied every 3 or 4 days on alternate sides of the lower abdomen.
All patients received 1000 mg of oral elemental calcium daily.
The average baseline lumbar spine T-score was -0.64 (range -2.7 to 3.8).
The % changes in BMD from baseline are illustrated in Figure 3.
Figure 3: Mean % change in BMD from baseline at 1 and 2 years after initiation of therapy with Placebo and Alora 0.025, 0.05, and 0.075 mg/day in the completer and intent-to-treat population with last observation carried forward (LOCF).
A total of 196 patients (44 – 0.025 mg/d, 49 – 0.05 mg/d, 45 – 0.075 mg/d, and 58 – placebo) were included in the completer population compared with 258 patients (59 – 0.025 mg/d, 64 – 0.05 mg/d, 63 – 0.075 mg/d, and 72 – placebo) in the intent-to-treat, last observation carried forward population.
All Alora doses were statistically superior to placebo for the primary endpoint, percent change in BMD from baseline.
The mean 2-year (LOCF) percent changes in BMD for 0.025 mg/d, 0.05 mg/d, 0.075 mg/d, and placebo were 1.45%, 3.39%, 4.24%, and –0.80% respectively.
Women’s Health Initiative Studies The Women’s Health Initiative (WHI) enrolled a total of 27,000 predominantly healthy postmenopausal women to assess the risks and benefits of either the use of 0.625 mg conjugated estrogens (CE) per day alone or the use of oral 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate (MPA) per day compared to placebo in the prevention of certain chronic diseases.
The primary endpoint was the incidence of coronary heart disease (CHD) [nonfatal myocardial infarction and CHD death], with invasive breast cancer as the primary adverse outcome studied.
A “global index” included the earliest occurrence of CHD, invasive breast cancer, stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, or death due to other cause.
The study did not evaluate the effects of CE or CE/MPA on menopausal symptoms.
The CE/MPA substudy was stopped early because, according to the predefined stopping rule, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the “global index.” Results of the CE/MPA substudy, which included 16,608 women (average age of 63 years, range 50 to 79; 83.9% White, 6.5% Black, 5.5% Hispanic), after an average follow-up of 5.2 years are presented in Table 4 below: Table 4 Relative and Absolute Risk Seen in the CE/MPA Substudy of WHIa.
Eventc Relative Risk CE/MPA vs.
placebo at 5.2 years (95% CI*) Placebo n=8102 CE/MP A n=8506 Absolute Risk per 10,000 Person-years CHD events 1.29 (1.02-1.63) 30 37 Non-fatal MI 1.32 (1.02-1.72) 23 30 CHD death 1.18 (0.70-1.97) 6 7 Invasive breast cancerb 1.26 (1.00-1.59) 30 38 Stroke 1.41 (1.07-1.85) 21 29 Pulmonary embolism 2.13 (1.39-3.25) 8 16 Colorectal cancer 0.63 (0.43-0.92) 16 10 Endometrial cancer 0.83 (0.47-1.47) 6 5 Hip fracture 0.66 (0.45-0.98) 15 10 Death due to causes other than the events above 0.92 (0.74-1.14) 40 37 Global Indexc 1.15 (1.03-1.28) 151 170 Deep vein thrombosisd 2.07 (1.49-2.87) 13 26 Vertebral fracturesd 0.66 (0.44-0.98) 15 9 Other osteoporotic fracturesd 0.77 (0.69-0.86) 170 131 a adapted from JAMA, 2002; 288:321-333 b includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer c a subset of the events was combined in a “global index”, defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes d not included in Global Index * normal confidence intervals unadjusted for multiple looks and multiple comparisons For those outcomes included in the “global index,” absolute excess risks per 10,000 person-years in the group treated with CE/MPA were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures.
The absolute excess risk of events included in the “global index” was 19 per 10,000 women-years.
There was no difference between the groups in terms of all-cause mortality [see BOX WARNING and WARNINGS and PRECAUTIONS].
Women’s Health Initiative Memory Study The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47% were age 65 to 69 years, 35% were 70 to 74 years, and 18% were 75 years of age and older) to evaluate the effects of CE/MPA (0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate) on the incidence of probable dementia (primary outcome) compared with placebo.
After an average follow-up of 4 years, 40 women in the estrogen/progestin group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 women-years) were diagnosed with probable dementia.
The relative risk of probable dementia in the hormone therapy group was 2.05 (95% CI, 1.21 to 3.48) compared to placebo.
Differences between groups became apparent in the first year of treatment.
It is unknown whether these findings apply to younger postmenopausal women [see BOX WARNING and WARNINGS, Dementia and PRECAUTIONS, Geriatric Use].
Drug Description Find Lowest Prices on MINIVELLE™ (estradiol) Transdermal System WARNING ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.
Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.
Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see WARNINGS AND PRECAUTIONS].
Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo.
It is unknown whether this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, Use in Specific Populations, and Clinical Studies].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo.
It is unknown whether this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, Use in Specific Populations, and Clinical Studies].
Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
DESCRIPTION MINIVELLE (estradiol transdermal system) contains estradiol in a multipolymeric adhesive.
The system is designed to release estradiol continuously upon application to intact skin.
Four dosage strengths of MINIVELLE are available to provide nominal in vivo delivery rates of 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per day via the skin.
Each corresponding system has an active surface area of 2.48, 3.30, 4.95, or 6.6 cm² and contains 0.62, 0.83, 1.24, or 1.65 mg of estradiol USP, respectively.
The composition of the systems per unit area is identical.
Estradiol USP is a white, crystalline powder, chemically described as estra-1,3,5 (10)-triene-3,17β-diol.
The structural formula is The molecular formula of estradiol is C18H24O2.
The molecular weight is 272.39 MINIVELLE is comprised of three layers.
Proceeding from the visible surface toward the surface attached to the skin, these layers are (1) a polyester film laminate (2) an adhesive formulation containing estradiol, acrylic adhesive, silicone adhesive, oleyl alcohol, NF, povidone, USP and dipropylene glycol, and (3) a polyester release liner which is attached to the adhesive surface and must be removed before the system can be used.
The active component of the system is estradiol.
The remaining components of the system are pharmacologically inactive.
Drug Description Find Lowest Prices on Menostar (estradiol) Transdermal System WARNING ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.
Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.
Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed, persis tent or recurring abnormal genital bleeding [see WARNINGS AND PRECAUTIONS].
Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo.
It is unknown whether this finding applies to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, Use in Specific Populations, and Clinical Studies].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other forms of estrogens.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration cons is tent with treatment goals and risks for the individual woman.
Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plusprogestin therapy should not be used for the prevention of cardiovascular disease or dementia [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
The WHI estrogen plusprogestin sub study reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyproges terone acetate (MPA) [2.5 mg], relative to placebo [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo.
It is unknown whether this finding applies to younger pos tmenopaus al women [see WARNINGS AND PRECAUTIONS, Use in Specific Populations, and Clinical Studies].
Breast Cancer The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.
Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration cons is tent with treatment goals and risks for the individual woman.
DESCRIPTION Menostar (estradiol transdermal system) is designed to provide nominal in vivo delivery of 14 mcg of estradiol per day continuously upon application to intact skin.
The period of use is 7 days.
The transdermal system has a contact surface area of 3.25 cm², and contains 1 mg of estradiol USP.
Estradiol USP is a white, crystalline powder, chemically described as estra-1,3,5(10)-triene-3, 17ßdiol.
It has an empirical formula of C18H24O2 and molecular weight of 272.38.
The structural formula is: The Menostar transdermal system comprises three layers.
Proceeding from the visible surface toward the surface attached to the skin, these layers are: A translucent polyethylene film.
An acrylate adhesive matrix containing estradiol USP.
A protective liner of siliconized or fluoropolymer-coated polyester film is attached to the adhesive surface and must be removed before the transdermal system can be used.
The active component of the transdermal system is estradiol.
The remaining components of the transdermal system (acrylate copolymer adhesive, fatty acid esters, and polyethylene backing) are pharmacologically inactive.
Drug Description Find Lowest Prices on Alora® (estradiol) Transdermal System, USP Continuous Delivery for Twice Weekly Dosing WARNING ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER.
Close clinical surveillance of all women taking estrogens is important.
Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
There is currently no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose [see WARNINGS, Malignant Neoplasms, Endometrial cancer].
Cardiovascular And Other Risks Estrogens with and without progestins should not be used for the prevention of cardiovascular disease or dementia [see WARNINGS, Cardiovascular Disorders and Dementia].
The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo [see CLINICAL PHARMACOLOGY and Clinical Studies and WARNINGS, Cardiovascular Disorders and Malignant Neoplasms, Breast cancer].
The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo.
It is unknown whether this finding applies to younger postmenopausal women [see CLINICAL PHARMACOLOGY and Clinical Studies and WARNINGS, Dementia and PRECAUTIONS, Geriatric Use].
Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar.
Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
DESCRIPTION Alora (Estradiol Transdermal System, USP) is designed to deliver estradiol continuously and consistently over a 3 or 4-day interval upon application to intact skin.
Four strengths of Alora are available, having nominal in vivo delivery rates of 0.025, 0.05, 0.075, and 0.1 mg estradiol per day through skin of average permeability (inter-individual variation in skin permeability is approximately 20%).
Alora has contact surface areas of 9 cm2, 18 cm2, 27 cm2, and 36 cm2 and contains 0.77, 1.5, 2.3, and 3.1 mg of estradiol, USP, respectively.
The composition of the estradiol transdermal systems per unit area is identical.
Estradiol, USP is a white, crystalline powder that is chemically described as estra-1,3,5(10)-triene-3, 17β-diol, has an empirical formula of C18H24O2 and has molecular weight of 272.39.
The structural formula is: Aloraconsists of three layers.
Proceeding from the polyethylene backing film as shown in the cross-sectional view below, the adhesive matrix drug reservoir that is in contact with the skin consists of estradiol, USP and sorbitan monooleate dissolved in an acrylic adhesive matrix.
The polyester overlapped release liner protects the adhesive matrix during storage and is removed prior to application of the system to the skin.
Product meets USP Drug Release Test 3.
Indications & Dosage INDICATIONS MINIVELLE is indicated for treatment of moderate to severe vasomotor symptoms due to menopause.
DOSAGE AND ADMINISTRATION Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer.
A woman without a uterus does not need a progestin.
In some cases, however, hysterectomized women with a history of endometriosis may need a progestin [see WARNINGS AND PRECAUTIONS].
Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.
Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
Treatment of Moderate to Severe Vasomotor Symptoms Start therapy with MINIVELLE 0.0375 mg per day applied to the skin twice weekly.
Dosage adjustment should be guided by the clinical response.
Therapy should be started at the lowest effective dose and the shortest duration consistent with the treatment goals.
Attempts to taper or discontinue the medication should be made at 3 to 6 month intervals.
The adhesive side of MINIVELLE should be placed on a clean, dry area on the lower abdomen (below the umbilicus) or buttocks.
MINIVELLE should not be applied to the breasts.
MINIVELLE should be replaced twice weekly (every 3-4 days).
The sites of application must be rotated, with an interval of at least 1 week allowed between applications to a particular site.
The area selected should not be oily, damaged, or irritated.
The waistline should be avoided, since tight clothing may rub the system off.
The system should be applied immediately after opening the pouch and removing the protective liner.
The system should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact with the skin, especially around the edges.
In the event that a system should fall off, the same system may be reapplied.
If the same system cannot be reapplied, a new system should be applied to another location.
If a woman has forgotten to apply a patch, she should apply a new patch as soon as possible.
In either case, the original treatment schedule should be continued.
The interruption of treatment in women taking MINIVELLE might increase the likelihood of breakthrough bleeding, spotting and recurrence of symptoms.
HOW SUPPLIED Dosage Forms And Strengths Transdermal system 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day.
MINIVELLE (estradiol transdermal system), 0.0375 mg per day - each 2.48 cm² system contains 0.62mg of estradiol USP for nominal* delivery of 0.0375 mg of estradiol per day.
Patient Calendar Pack of 8 Systems…………………..NDC 68968-6637-8 Carton of 3 Patient Calendar Packs of 8 Systems…….NDC 68968-6637-3 MINIVELLE (estradiol transdermal system), 0.05 mg per day - each 3.3 cm² system contains 0.83 mg of estradiol USP for nominal* delivery of 0.05 mg of estradiol per day.
Patient Calendar Pack of 8 Systems………………….NDC 68968-6650-x Carton of 3 Patient Calendar Packs of 8 Systems……NDC 68968-6650-x MINIVELLE (estradiol transdermal system), 0.075 mg per day - each 4.95 cm² system contains 1.24 mg of estradiol USP for nominal* delivery of 0.075 mg of estradiol per day.
Patient Calendar Pack of 8 Systems………………….NDC 68968-6675-8 Carton of 3 Patient Calendar Packs of 8 Systems……NDC 68968-6675-3 MINIVELLE (estradiol transdermal system), 0.1 mg per day - each 6.6 cm² system contains 1.65mg of estradiol USP for nominal* delivery of 0.1 mg of estradiol per day.
Patient Calendar Pack of 8 Systems………………….NDC 68968-6610-8 Carton of 3 Patient Calendar Packs of 8 Systems……NDC 68968-6610-3 * See DESCRIPTION Storage and Handling Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).
Do not store unpouched.
Apply immediately upon removal from the protective pouch.
Used transdermal systems still contain active hormone.
To discard, fold the sticky side of the transdermal system together, place it in a sturdy child-proof container, and place this container in the trash.
Used transdermal systems should not be flushed in the toilet.
Manufactured by: Noven Pharmaceuticals Inc., Miami, FL 33186.
Approved 10/2012
Indications & Dosage INDICATIONS Prevention Of Postmenopausal Osteoporosis Limitation Of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.
DOSAGE AND ADMINISTRATION Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer.
It is recommended that women who have a uterus and are treated with Menostar receive a progestin for 14 days every 6 to 12 months and undergo an endometrial biopsy at yearly intervals or as clinically indicated in order to detect any endometrial stimulation which might require further clinical action.
A women without a uterus does not need a progestin.
In some cases, however, hysterectomized women with a history of endometriosis may need a progestin [see WARNINGS AND PRECAUTIONS].
Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.
Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
Prevention Of Postmenopausal Osteoporosis Menostar 14 mcg per day applied to a clean dry area of the lower abdomen once weekly.
Application Of The Menostar Transdermal System Site Selection The adhesive side of Menostar should be placed on a clean, dry area of the lower abdomen or the upper quadrant of the buttock.
Menostar should not be applied to or near the breasts.
The sites of application must be rotated, with an interval of at least 1-week allowed between applications to a same site.
The area selected should not be oily, damaged, or irritated.
The waistline should be avoided, since tight clothing may rub the transdermal system off.
Application to areas where sitting would dislodge Menostar should also be avoided.
Application Menostar should be applied immediately after opening the pouch and removing the protective liner.
Menostar should be pressed firmly in place with the fingers for at least 10 seconds, making sure there is good contact, especially around the edges.
If the system lifts, apply pressure to maintain adhesion.
In the event that a system should fall off reapply it to a different location.
If the system cannot be reapplied, a new system should be applied for the remainder of the 7-day dosing interval.
Only one system should be worn at any one time during the 7-day dosing interval.
Swimming, bathing, or using a sauna while using Menostar has not been studied, and these activities may decrease the adhesion of the system and the delivery of estradiol.
Removal Of The Menostar Transdermal System Removal of the system should be done carefully and slowly to avoid irritation of the skin.
Should any adhesive remain on the skin after removal of the system, allow the area to dry for 15 minutes.
Then gently rubbing the area with an oil-based cream or lotion should remove the adhesive residue.
Used patches still contain some active hormones.
Each patch should be carefully folded in half so that it sticks to itself before throwing it awa HOW SUPPLIED Dosage Forms And Strengths Menostar (estradiol transdermal system) 14 mcg per day - each 3.25 cm² system contains 1 mg of estradiol.
Menostar (estradiol transdermal system), 14 mcg per day - each 3.25 cm system contains 1 mg of estradiol USP Individual Carton of 4 systems NDC 50419-455-04 Storage And Handling Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F°F and 86°F).
Do not store above 86°F (30°C).
Do not store unpouched.
Apply immediately upon removal from the protective pouch.
Used transdermal systems still contain active hormone.
To discard, fold the sticky side of the transdermal system together, place it in a child-proof container, and place this container in the trash.
Used transdermal systems should not be flushed in the toilet.
Manufactured by 3M Drug Delivery Systems, Northridge, CA 91324.
Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981.
Revised: Jul 2015
Indications & Dosage INDICATIONS Alora is indicated in: Treatment of moderate to severe vasomotor symptoms associated with the menopause.
Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause.
When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.
Prevention of postmenopausal osteoporosis.
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.
The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and, when indicated, pharmacologic therapy.
Postmenopausal women require an average of 1500 mg/day of elemental calcium to remain in neutral calcium balance.
Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake.
Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.
DOSAGE AND ADMINISTRATION Alora should be administered twice weekly, as instructed.
The adhesive side of the Alora system should be placed on a clean, dry area of skin.
The recommended application site is the lower abdomen.
In addition, the upper quadrant of the buttocks or outer aspect of the hip may be used.
Alora should not be applied to the breasts.
The sites of application should be rotated, with an interval of at least 1 week allowed between applications to a particular site.
The area selected should not be oily, damaged, or irritated.
The waistline should be avoided, since tight clothing may rub the system off.
The system should be applied immediately after opening the pouch and removing the protective liner.
The system should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges.
In the event that a system should fall off, the same system may be reapplied.
If necessary, a new system may be applied to another site.
The original treatment schedule should be maintained.
Initiation Of Therapy For treatment of moderate-to-severe vasomotor symptoms, vulvar and vaginal atrophy associated with the menopause, hypogonadism, castration, or primary ovarian failure, treatment is usually initiated with Alora 0.05 mg/day applied to the skin twice weekly.
The lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible.
Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals.
For the prevention of postmenopausal osteoporosis, the minimum dose of Alora that has been studied and shown to be effective is 0.025 mg/day applied to the skin twice weekly.
Bone mineral density measurements should be repeated to monitor treatment efficacy.
The dosage may be increased as necessary, depending on bone mineral density and adverse events.
In women who are not currently taking oral estrogens or in women switching from topical therapy or another transdermal estradiol therapy, treatment with Alora can be initiated at once.
In women who are currently taking oral estrogens, treatment with Alora should be initiated 1 week after withdrawal of oral therapy or sooner if menopausal symptoms reappear in less than 1 week.
When estrogen is prescribed for a postmenopausal woman with a uterus, progestin should also be initiated to reduce the risk of endometrial cancer.
A woman without a uterus does not need progestin.
Use of estrogen, alone or in combination with a progestin, should be limited to the shortest duration consistent with treatment goals and risks for the individual woman.
Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary [see BOX WARNING and WARNINGS].
For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Therapeutic Regimen Alora may be administered in a continuous regimen in patients who do not possess an intact uterus.
In those patients with an intact uterus who are not using concomitant progestin therapy, Alora can be administered on a cyclic schedule (e.g., 3 weeks of therapy followed by 1 week without) for the treatment of postmenopausal symptoms.
However, no studies have been conducted using this intermittent regimen for the prevention of postmenopausal osteoporosis.
HOW SUPPLIED Alora (Estradiol Transdermal System, USP) 0.025 mg/day.
Each 9 cm2 system contains 0.77 mg of estradiol, USP for nominal delivery of 0.025 mg of estradiol per day when dosed in a twice weekly regimen.
NDC 0023-5885-12 Patient Calendar Box of 8 Systems Alora (Estradiol Transdermal System, USP) 0.05 mg/day.
Each 18 cm2 system contains 1.5 mg of estradiol, USP for nominal delivery of 0.05 mg of estradiol per day when dosed in a twice weekly regimen.
NDC 0023-5886-15 Patient Calendar Box of 8 Systems Alora (Estradiol Transdermal System, USP) 0.075 mg/day.
Each 27 cm2 system contains 2.3 mg of estradiol, USP for nominal delivery of 0.075 mg of estradiol per day when dosed in a twice weekly regimen.
NDC 0023-5887-17 Patient Calendar Box of 8 Systems Alora (Estradiol Transdermal System, USP) 0.1 mg/day.
Each 36 cm2 system contains 3.1 mg of estradiol, USP for nominal delivery of 0.1 mg of estradiol per day when dosed in a twice weekly regimen.
NDC 0023-5888-11 Patient Calendar Box of 8 Systems Store at 20-25°C (68-77°F).
[See USP controlled room temperature.] Do not store unpouched.
Apply immediately upon removal from the protective pouch.
Discard used Alora in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.
Keep out of reach of children.
Distributed By: Allergan USA, Inc.
Irvine, CA 92612.
Revised: Nov 2017
Medication Guide PATIENT INFORMATION MINIVELLE (MIN-ee-vell) (estradiol) Transdermal System Read this patient information before you start using MINIVELLE and each time you get a refill.
There may be new information.
This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment.
What is the most important information I should know about MINIVELLE (an estrogen hormone)? Using estrogen-alone may increase your chance of getting cancer of the uterus (womb).
Report any unusual vaginal bleeding right away while you are using MINIVELLE.
Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Your healthcare provider should check any unusual vaginal bleeding to find out the cause Do not use estrogen-alone to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function) Using estrogen-alone may increase your chances of getting strokes or blood clots Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes, or dementia Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older You and your healthcare provider should talk regularly about whether you still need treatment with MINIVELLE What is MINIVELLE? MINIVELLE is a prescription medicine patch that contains estradiol (an estrogen hormone).
What is MINIVELLE™ used for? THE MINIVELLE patch is used after menopause to: Reduce moderate to severe hot flashes Estrogens are hormones made by a woman's ovaries.
The ovaries normally stop making estrogens when a woman is between 45 and 55 years old.
This drop in body estrogen levels causes the “change of life” or menopause (the end of monthly menstrual periods).
Sometimes, both ovaries are removed during an operation before natural menopause takes place.
The sudden drop in estrogen levels causes “surgical menopause.” When the estrogen levels begin dropping, some women develop very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest or sudden strong feelings of heat and sweating (“hot flashes” or “hot flushes”).
In some women, the symptoms are mild and they will not need treatment with estrogen therapy.
In other women, symptoms can be more severe.
You and your healthcare provider should talk regularly about whether or not you still need treatment with MINIVELLE.
Who should not use MINIVELLE? Do not start using MINIVELLE if you: have unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
currently have or have had certain cancers Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus.
If you have or have had cancer, talk with your healthcare provider about whether you should use MINIVELLE.
had a stroke or heart attack currently have or have had blood clots currently have or have had liver problems have been diagnosed with a bleeding disorder are allergic to MINIVELLE or any of its ingredients See the list of ingredients in MINIVELLE at the end of this leaflet.
think you may be pregnant MINIVELLE is not for pregnant women.
If you think you may be pregnant, you should have a pregnancy test and know the results.
Do not take MINIVELLE if the test is positive and talk to your healthcare provider.
What should I tell my healthcare provider before I use MINIVELLE? Before you use MINIVELLE, tell your healthcare provider if you: have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
have any other medical conditions Your healthcare provider may need to check you more carefully if you have certain conditions such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.
are going to have surgery or will be on bed rest.
Your healthcare provider will let you know if you need to stop using MINIVELLE.
are breast feeding The hormone in MINIVELLE can pass into your breast milk.
Tell your healthcare provider about all the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements.
Some medicines may affect how MINIVELLE works.
MINIVELLE may also affect how your other medicines work.
Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
How should I use MINIVELLE? For detailed instructions, see the step-by-step instructions for using MINIVELLE at the end of this Patient Information Use MINIVELLE exactly as your healthcare provider tells you to use it MINIVELLE is for skin use only Change your MINIVELLE patch 2 times a week or every 3 to 4 days Apply your MINIVELLE patch to a clean, dry area on your lower abdomen or buttocks.
This area must be clean, dry, and free of powder, oil or lotion for your patch to stick to your skin Apply your MINIVELLE patch to a different area of your abdomen or your buttocks each time.
Do not use the same application site 2 times in the same week.
Do not apply MINIVELLE to your breasts If you forget to apply a new MINIVELLE patch, you should apply a new patch as soon as possible.
You and your healthcare provider should talk regularly (every 3 to 5 months) about your dose and whether you still need treatment with MINIVELLE.
How to Change MINIVELLE When changing the patch, peel off the used patch slowly from the skin After removal of MINIVELLE, patients usually have either no adhesive residue or light adhesive residue.
If any adhesive residue remains on your skin after removing the patch, allow the area to dry for 15 minutes.
Then, gently rub the area with oil or lotion to remove the adhesive from your skin Keep in mind, the new patch must be applied to a different area of your abdomen or buttocks.
This area must be clean, dry, cool and free of powder, oil or lotion What are the possible side effects of MINIVELLE? Side effects are grouped by how serious they are and how often they happen when you are treated.
Serious, but less common side effects include: heart attack stroke blood clots dementia breast cancer cancer of the lining of the uterus (womb) cancer of the ovary high blood pressure high blood sugar gallbladder disease liver problems changes in your thyroid hormone levels enlargement of benign tumors (“fibroids”) Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: new breast lumps unusual vaginal bleeding changes in vision or speech sudden new severe headaches severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Less serious, but common side effects include: headache breast pain irregular vaginal bleeding or spotting stomach or abdominal cramps, bloating nausea and vomiting hair loss fluid retention vaginal yeast infection redness and/or irritation at patch placement site These are not all the possible side effects of MINIVELLE.
For more information, ask your healthcare provider or pharmacist.
Tell your healthcare provider if you have any side effects that bother you or does not go away.
You may report side effects to Noven at 1-800-445-8070 or to FDA at 1-800-FDA-1088.
What can I do to lower my chances of a serious side effect with MINIVELLE? Talk with your healthcare provider regularly about whether you should continue taking MINIVELLE If you have a uterus, talk to your healthcare provider about whether the addition of a progestin is right for you The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb).
See your healthcare provider right away if you get vaginal bleeding while using MINIVELLE Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances of getting heart disease Ask your healthcare provider for ways to lower your chances of getting heart disease.
How should I store and throw away used MINIVILLE patches? Store at room temperature 68°F to 77°F (20°C to 25°C) Do not store MINIVILLE patches outside of their pouches.
Apply immediately upon removal from the protective pouch Used patches still contain estrogen.
To throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash.
Used patches should not be flushed in the toilet KEEP MINIVELLE and all other medicines out of the reach of children General information about safe and effective use of MINIVELLE Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets.
Do not use MINIVELLE for conditions for which it was not prescribed.
Do not give MINIVELLE to other people, even if they have the same symptoms you have.
It may harm them.
This leaflet summarizes the most important information about MINIVELLE.
If you would like more information, talk with your healthcare provider or pharmacist.
You can ask your healthcare provider or pharmacist for information about MINIVELLE that is written for health professionals.
For more information, go to www.minivelle.com or call Noven Pharmaceuticals Inc at 1-800-445-8070.
What are the ingredients in MINIVELLE? Active ingredient: estradiol Inactive ingredient: Polyester film laminate, acrylic and silicone adhesives, oleyl alcohol, NF, povidone, USP and dipropylene glycol and a polyester release liner Instructions for Use MINIVELLE (MIN-ee-vell) (estradiol transdermal system) Read this PATIENT INFORMATION before you start using MINIVELLE and each time you get a refill.
There may be new information.
This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment.
You will need the following supplies: See Figure A Figure A Step 1: Pick the days you will change your patch.
You will need to change your patch 2 times a week or every 3 to 4 days.
Use the calendar printed inside your carton to choose the 2 days you will change your patch See Figure B Remember to change your patch on the same 2 days you marked on your calendar.
If you forget to change your patch on the correct date, apply a new patch as soon as you remember, and continue to follow your original schedule Figure B Step 2: Remove the MINIVELLE patch from the pouch.
Remove the patch from its protective pouch by tearing at the notch (do not use scissors) See Figure C Do not remove your patch from the protective pouch until you are ready to apply it Figure C Step 3: Remove half of the adhesive liner.
See Figure D Figure D Step 4: Placing the patch on your skin.
Hold the part of the patch that still has the adhesive liner on it Avoid touching the sticky half of the patch with your fingers Apply the exposed sticky half of the patch to 1 of the areas of skin shown below (See Figures E and F) Figure E Figure F Note: Avoid the waistline, since clothing and belts may cause the patch to be rubbed off Do not apply the patch to your breasts Only apply the patch to skin that is clean, dry, and free of any powder, oil, or lotion You should not apply the patch to injured, burned, or irritated skin, or areas with skin conditions (such as birth marks, tattoos, or that is very hairy) Step 5: Press the patch firmly onto your skin.
Remove the remaining half of the adhesive liner and press the entire patch into place with the palm of your hand for 10 seconds Rub the edges of the patch with your fingers to make sure that it will stick to your skin.
(See Figure G) Figure G Note: Showering will not cause your patch to fall off If your patch falls off reapply it.
If you cannot reapply the patch, apply a new patch to another area (See Figures E and D) and continue to follow your original placement schedule If you stop using your MINIVELLE patch or forget to apply a new patch as scheduled, you may have spotting, or bleeding, and recurrence of symptoms Step 6: Throwing away your used patch.
When it is time to change your patch, remove the old patch before you apply a new patch To throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash.
Used patches should not be flushed in the toilet This Patient Information and Instructions for Use have been approved by the U.S Food and Drug Administration.
Medication Guide PATIENT INFORMATION MENOSTAR (Men-o-star) (estradiol) Transdermal System Read this Patient Information before you start using MENOSTAR and each time you get a refill.
There may be new information.
This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment.
What is the most important information I should know about MENOSTAR (an estrogen hormone)? Using estrogen-alone may increase your chance of getting cancer of the uterus (womb).
Report any unusual vaginal bleeding right away while you are using MENOSTAR.
Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
Do not use estrogen-alone to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function).
Using estrogen-alone may increase your chances of getting strokes or blood clots.
Using estrogen-alone may increase your chance of getting dementia, based on a study of women age 65 years of age or older.
Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia.
Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.
Using estrogens with progestins may increase your chance of getting dementia, based on a study of women age 65 years of age or older.
You and your healthcare provider should talk regularly about whether you still need treatment with MENOSTAR.
What is MENOSTAR? MENOSTAR is a prescription medicine patch (Transdermal System) that contains estradiol (an estrogen hormone).
What is MENOSTAR used for? MENOSTAR is used after menopause to: Help reduce your chances of getting osteoporosis (thin weak bones) If you use MENOSTAR only to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you.
Who should not use MENOSTAR? Do not start using MENOSTAR if you: have unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
currently have or have had certain cancers Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus.
If you have or have had cancer, talk with your healthcare provider about whether you should use MENOSTAR.
had a stroke or heart attack currently have or have had blood clots currently have or have had liver problems have been diagnosed with a bleeding disorder are allergic to MENOSTAR or any of its ingredients See the list of ingredients in MENOSTAR at the end of this leaflet.
think you may be pregnant MENOSTAR is not for pregnant women.
If you think you may be pregnant, you should have a pregnancy test and know the results.
Do not use MENOSTAR if the test is positive and talk to your healthcare provider.
What should I tell my healthcare provider before I use MENOSTAR? Before you use MENOSTAR, tell your healthcare provider if you: have any unusual vaginal bleeding Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
have any other medical conditions Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, angioedema (swelling of face and tongue), or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.
are going to have surgery or will be on bed rest Your healthcare provider will let you know if you need to stop using MENOSTAR.
are breastfeeding The hormone in MENOSTAR can pass into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.
Some medicines may affect how MENOSTAR works.
MENOSTAR may also affect how your other medicines work.
Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
How should I use MENOSTAR? For detailed instructions, see the step-by-step instructions for using MENOSTAR at the end of this Patient Information.
Use MENOSTAR exactly as your healthcare provider tells you to use it.
MENOSTAR is for skin use only.
Change your MENOSTAR patch 1 time each week or every 7 days.
Apply your MENOSTAR patch to a clean, dry area on your lower abdomen or buttocks.
This area must be clean, dry, and free of powder, oil or lotion for your patch to stick to your skin.
Apply your MENOSTAR patch to a different area of your abdomen or your buttocks each time.
Do not use the same application site 2 times in the same week.
Do not apply MENOSTAR to your breasts.
If you forget to apply a new MENOSTAR patch, you should apply a new patch as soon as possible.
You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are using and whether you still need treatment with MENOSTAR.
How to Change MENOSTAR.
When changing MENOSTAR, peel off the used patch slowly from the skin.
After removal of MENOSTAR, people usually have either no adhesive residue or light adhesive residue.
If any adhesive residue remains on your skin after removing the patch, allow the area to dry for 15 minutes.
Then, gently rub the area with an oil-based cream or lotion to remove the adhesive from your skin.
Keep in mind, the new patch must be applied to a different skin area of your abdomen or buttocks.
This area must be clean, dry, and free of powder, oil or lotion.
The same site should not be used again for at least 1 week after removal of the patch.
What are the possible side effects of MENOSTAR? Side effects are grouped by how serious they are and how often they happen when you are treated.
Serious, but less common side effects include: heart attack stroke blood clots dementia breast cancer cancer of the lining of the uterus (womb) cancer of the ovary high blood pressure high blood sugar gallbladder disease liver problems changes in your thyroid hormone levels enlargement of benign tumors of the uterus (“fibroids”) Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: new breast lumps unusual vaginal bleeding changes in vision or speech sudden new severe headaches severe pains in your chest or legs with or without shortness of breath, weakness and fatigue Less serious, but common side effects include: headache breast tenderness or pain irregular vaginal bleeding or spotting stomach or abdominal cramps, bloating nausea and vomiting hair loss fluid retention vaginal yeast infection redness or irritation at the patch placement site These are not all the possible side effects of MENOSTAR.
For more information, ask your healthcare provider or pharmacist.
Tell your healthcare provider if you have any side effects that bother you or does not go away.
You may report side effects to Bayer Healthcare Pharmaceuticals at 1-888-842-2937 or to FDA at 1-800-FDA-1088.
What can I do to lower my chances of a serious side effect with MENOSTAR? Talk with your healthcare provider regularly about whether you should continue using MENOSTAR.
If you have a uterus, talk with your healthcare provider about whether the addition of a progestin is right for you.
The addition of a progestin is generally recommended for women with a uterus to reduce the chance of getting cancer of the uterus (womb).
See your healthcare provider right away if you get vaginal bleeding while using MENOSTAR.
Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else.
If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.
If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances of getting heart disease.
Ask your healthcare provider for ways to lower your chances of getting heart disease.
How should I store and throw away used MENOSTAR? Store MENOSTAR at room temperature 68°F to 77°F (20°C to 25°C).
Do not store MENOSTAR patches outside of their pouches.
Apply immediately upon removal from the protective pouch.
Used patches still contain estrogen.
To throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash.
Used patches should not be flushed in the toilet.
Keep MENOSTAR and all medicines out of the reach of children.
General information about the s afe and effective us e of MENOSTAR.
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets.
Do not use MENOSTAR for conditions for which it was not prescribed.
Do not give MENOSTAR to other people, even if they have the same symptoms you have.
It may harm them.
This leaflet summarizes the most important information about MENOSTAR.
If you would like more information, talk with your healthcare provider or pharmacist.
You can ask for information about MENOSTAR that is written for health professionals.
For more information, go to www.menostar-us.com or call Bayer Healthcare Pharmaceuticals Inc.
at 1-888-842-2937.
What are the ingredients in MENOSTAR? Active ingredient: estradiol Inactive ingredients: acrylate copolymer adhesive, fatty acid esters, and polythylene backing.
Instructions for Use MENOSTAR (Men-o-star) (estradiol transdermal system) Read this Patient Information before you start using MENOSTAR and each time you get a refill.
There may be new information.
This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment.
You will need the following supplies : See Figure A Figure A Step 1: Pick the days you will change your MENOSTAR.
You will need to change your patch 1 time each week or every 7 days.
Step 2.
Remove the MENOSTAR patch from the pouch.
Remove the patch from its protective pouch by tearing at the notch (do not use scissors).
See Figure B Do not remove your patch from the protective pouch until you are ready to apply it.
Figure B Step 3.
Remove the adhesive liner.
See Figure C You will see that MENOSTAR is an oval shaped clear patch that is attached to a thick, hardplastic adhesive liner and covered by a clear, plastic film.
See Figure C To apply your patch you must first remove the protective, clear plastic film that is attached to the clear thicker plastic backing.
See Figure D There is a silver foil-sticker attached to the inside of the pouch.
Do not remove the silver foil sticker from the pouch.
See Figure E Figure C, D and Figure E Step 4.
Placing the patch on your skin.
Apply the sticky side of the patch to 1 of the areas of skin shown below.
(See Figure F and Figure G) Do not touch the sticky side of the patch with your fingers.
Figure F and G Note: Avoid the waistline, since clothing and belts may cause the patch to be rubbed off.
Do not apply MENOSTAR to your breasts.
Only apply MENOSTAR to skin that is clean, dry, and free of any powder, oil, or lotion.
You should not apply the patch to injured, burned, or irritated skin, or areas with skin conditions (such as birth marks, tattoos, or that is very hairy).
Step 5.
Press the patch firmly onto your skin.
Press the patch firmly in place with your fingers for at least 10 seconds.
Rub the edges of the patch to make sure that it will stick to your skin.
(See Figure H) Figure H Note: Contact with water while you are swimming, using a sauna, bathing, or showering may cause the patch to fall off.
If your patch falls off reapply it.
If you cannot reapply the patch, apply a new patch to another area (See Figure F and Figure G) and continue to follow your original application schedule.
If you stop using your MENOSTAR patch or forget to apply a new patch as scheduled, you may have spotting, or bleeding, or your symptoms may come back.
Step 6: Throwing away your used patch.
When it is time to change your patch, remove the old patch before you apply a new patch.
To throw away the patch, fold the sticky side of the patch together, place it in a sturdy child-proof container, and place this container in the trash.
Used patches should not be flushed in the toilet.
This Patient Information and Instructions for Use have been approved by the U.S Food and Drug Administration.
Medication Guide PATIENT INFORMATION Read this PATIENT INFORMATION before you start using Alora (ah-LORE-ah) and read what you get each time you refill Alora.
There may be new information.
This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT ALORA (AN ESTROGEN HORMONE)? Estrogens increase the chances of getting cancer of the uterus.
Report any unusual vaginal bleeding right away while you are taking estrogens.
Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, strokes, or dementia.
Using estrogens with or without progestins may increase your chances of getting heart attack, strokes, breast cancer, and blood clots.
Using estrogens with progestins may increase your risk of dementia.
You and your healthcare provider should talk regularly about whether you still need treatment with Alora.
What is Alora? Alora is a patch that contains the estrogen hormone estradiol.
When applied to the skin as directed below, the Alora patch releases estrogen through the skin into the abdomen.
What is Alora used for? Alora is used after menopause to: Reduce moderate or severe hot flashes.
Estrogens are hormones made by a woman’s ovaries.
Between ages 45 and 55, the ovaries normally stop making estrogens.
This drop in body estrogen levels causes the “change of life” or menopause (the end of monthly menstrual periods).
Sometimes, both ovaries are removed during an operation before natural menopause takes place.
The sudden drop in estrogen levels causes “surgical menopause.” When estrogen levels begin dropping, some women develop very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden intense episodes of heat and sweating (“hot flashes” or “hot flushes”).
In some women the symptoms are mild and they will not need estrogens.
In other women, symptoms can be more severe.
You and your healthcare provider should talk regularly about whether you still need treatment with Alora.
Treat moderate to severe dryness, itching, and burning in and around the vagina.
You and your healthcare provider should talk regularly about whether you still need treatment with Alora to control these problems.
If you use Alora only to treat your dryness, itching, and burning in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you.
Treat certain conditions in which a young woman’s ovaries do not produce enough estrogen naturally.
Help reduce your chances of getting osteoporosis (thin weak bones).
Osteoporosis from menopause is a thinning of the bones that makes them weaker and allows them to break more easily.
If you use Alora only to prevent osteoporosis from menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you.
Weight-bearing exercise like walking and running, and taking calcium and vitamin D supplements may lower your chances of getting postmenopausal osteoporosis.
It is important to talk about exercise and supplements with your healthcare provider before starting them.
Who Should Not Use Alora Do not use Alora if you: Have unusual vaginal bleeding.
Currently have or have had certain cancers.
Estrogens may increase the risk of certain types of cancer, including cancer of the breast or uterus.
If you have or have had cancer, talk to your healthcare provider about whether you should use Alora.
Had a stroke or heart attack in the past year.
Currently have or have had blood clots.
Currently have or have had liver problems.
Are allergic to Alora or any of the ingredients in it.
See the end of this leaflet for a list of ingredients in Alora.
Think you may be pregnant.
Tell your healthcare provider: If you are breastfeeding.
The hormone in Alora may pass into your milk.
About all of your medical problems.
Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing); epilepsy (seizures); migraine; endometriosis; lupus; problems with your heart; liver; thyroid; kidneys; or have high calcium levels in your blood.
About all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.
Some medicines may affect how Alora works.
Alora may also affect how your other medicines work.
If you are going to have surgery or will be on bed rest.
You may need to stop estrogens.
What Are the Possible Side Effects of Alora? Less common but serious side effects include: Breast cancer Cancer of the uterus Stroke Heart attack Blood clots Gallbladder disease Ovarian cancer Dementia These are some of the warning signs of serious side effects: Breast lumps Unusual vaginal bleeding Dizziness and faintness Changes in speech Severe headaches Chest pain Shortness of breath Pains in your legs Changes in vision Vomiting Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.
Common side effects include: Headache Breast pain Irregular vaginal bleeding or spotting Stomach/abdominal cramps, bloating Nausea and vomiting Hair loss Other side effects include: High blood pressure Liver problems High blood sugar Fluid retention Enlargement of benign tumors of the uterus (“fibroids”) Vaginal yeast infection These are not all the possible side effects of Alora.
For more information, ask your healthcare provider or pharmacist.
What Can I Do to Lower My Chances of Getting a Serious Side Effect with Alora? Talk with your healthcare provider regularly about whether you should continue using Alora.
If you have a uterus, talk to your healthcare provider right away about whether the addition of a progestin is right for you.
In general, the addition of a progestin is recommended for women with a uterus to reduce the chance of getting cancer of the uterus.
See your healthcare provider right away if you get vaginal bleeding while using Alora.
Have a breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else.
If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.
If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease.
Ask your healthcare provider for ways to lower your chances for getting heart disease.
How should I use Alora? Before you begin, read all the information in these 5 steps.
Step 1.
Choose your schedule for twice-a-week application.
Put on a new patch twice a week.
Use one of the schedules on the inside flap of the patch box.
For example, if you apply your first patch on Sunday, take that patch off on Wednesday and put on a new one.
Stay on this schedule as long as you use Alora.
To help remind yourself, mark the schedule on the inside flap of the patch box.
Put a check next to the first day you apply the patch.
When you change your patch, don’t put the new one in the same place.
To help reduce the chance of skin redness or irritation, wait at least 1 week before you reuse a spot.
Step 2.
Before you apply the patch make sure the skin at the spot is: Freshly washed, but dry and cool (wait a few minutes after taking a hot bath or shower).
Free of body powder or lotion.
Free of cuts, rashes, or any other skin problem.
Step 3.
Choose a spot for the patch Place the patch on the lower abdomen (below the panty line) when you first start using Alora.
As you get used to applying Alora, you may want to try the hips or buttocks to see which area works best for you.
Do not apply Alora to your breasts or any other parts of your body.
Step 4.
How to apply the patch Open the pouch that contains the patch.
Locate the notch on the top left or right corner of the pouch.
Hold the pouch at the notch and tear off the top edge.
Do not cut the pouch with scissors, which might damage the patch inside.
Pull the patch out.
Apply one half of the patch to your skin.
Remove half of the liner, which covers the sticky surface of the patch.
To find the liner, bend the patch in half.
Then grab the clear straight edge of the liner and pull that piece off.
Without touching the sticky surface, press the sticky half of the patch onto your skin.
(If you touch the sticky surface, the patch may not stay on as well.) Rub the sticky half firmly to ensure full contact with your skin.
Apply the second half of the patch to your skin.
Bend the patch back over itself.
Press down on the liner firmly.
Push the liner forward a little to loosen the edge.
Grab the loose edge at either corner and peel off the second piece of the liner.
Try not to touch the sticky surface of the patch.
Press the entire patch firmly onto the skin with your finger tips.
Press for at least 10 seconds to make sure the patch will stay in place.
Be sure all of it sticks to your skin, even around the edges.
To help the patch stay in place: Try not to disturb the patch while putting on and removing clothes.
It may help to place the patch where your underwear will cover it at all times.
Be careful while changing clothes, washing or drying off, so that you do not catch the patch with your clothes or the towel.
Try different sites on the lower abdomen, hips, or buttocks area to see what works well with your body and your clothing.
If the patch starts to lift, simply press it back in place.
Step 5.
Removing the patch Take off the old patch.
Fold it in half (sticky sides together) and throw it away out of the reach of children and pets.
The skin under the old patch may look pink, but the color should fade away soon.
In some cases, the skin may itch or look red; this may last from a couple of hours to a couple of days.
Most of the time this is minor, and goes away by itself.
But if it bothers you a lot or lasts longer than a few days, call your healthcare provider.
For Best Results, Stay with Your Patch Program Replace your patch twice each week, on the 2 days you have chosen.
Until it becomes a habit, try: Marking your schedule on the inside flap of the patch box; Marking the days on your calendar; Linking the days you change your patch to other things that always happen on those days (e.g., an exercise class, meetings, etc.).
Handle each patch with care.
Make sure the skin is clean, dry, and free of lotion and powder.
Try to avoid touching the sticky surface when applying the patch.
Be careful while changing clothes, washing or drying off, so that you do not catch the patch with your clothes or the towel.
If the patch starts to lift, simply press it back in place.
Keep working with your healthcare provider, pharmacist, or other healthcare professional.
Ask questions.
If you have concerns, talk them over -don’t just stop using the patch on your own.
Remember, it may take a little time and some experience to get accustomed to using a patch.
Estrogens should be used only as long as needed.
Start with the lowest dose and talk to your healthcare provider about how well that dose is working for you.
You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about whether you still need treatment with Alora.
Get your refills of the Alora patch before your supply runs out.
How should I store Alora? Store at 20-25°C (68-77°F).
[See USP controlled room temperature.] Do not store patches outside of their pouches.
Apply the patch as soon as you take it out of the protective pouch.
Discard used Alora in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.
General Information about the safe and effective use of Alora Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets.
Do not take Alora for conditions for which it was not prescribed.
Your healthcare provider has prescribed this drug for you and you alone.
Do not give the drug to anyone else.
It may harm them.
Keep Alora out of the reach of children.
This leaflet provides a summary of the most important information about Alora.
If you would like more information, talk with your healthcare provider.
You can ask for information about Alora that is written for health professionals.
What are the ingredients in Alora? Each patch contains estradiol, USP as the active component.
Inactive components of each patch include sorbitan monooleate, NF; acrylic adhesive; polyethylene film; and siliconized polyester film.
Keep out of reach of children.
Overdosage & Contraindications Side Effects & Drug Interactions SIDE EFFECTS The following serious adverse reactions are discussed elsewhere in labeling: Cardiovascular Disorders [see BOXED WARNING, WARNINGS AND PRECAUTIONS] Endometrial Cancer [see BOXED WARNING, WARNINGS AND PRECAUTIONS] Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
There were no clinical trials conducted with MINIVELLE.
MINIVELLE is bioequivalent to Vivelle®.
The following adverse reactions are reported with Vivelle: Table 1: Summary of Most Frequently Reported Adverse Reactions (Vivelle versus Placebo) Regardless of Relationship Reported at a Frequency > 5 Percent Vivelle 0.0375 mg/day† (N=130) N (%) Vivelle 0.05 mg/day† (N=103) N (%) Vivelle 0.075 mg/day† (N=46) N (%) Vivelle 0.1 mg/day† (N=132) N (%) Placebo (N=157) N (%) Gastrointestinal disorders Constipation 5 (3.8) 4 (3.9) 3 (6.5) 2 (1.5) 4 (2.5) Dyspepsia 12 (9.2) 3 (2.9) 2 (4.3) 0 10 (6.4) Nausea 8 (6.2) 4 (3.9) 0 7(5.3) 5 (3.2) General disorders and administration site conditions*** Influenza-like illness 6 (4.6) 8 (7.8) 0 3 (2.3) 10 (6.4) Pain NOS* 8 (6.2) 0 2 (4.3) 7 (5.3) 7(4.5) Infections and infestations Influenza 4 (3.1) 6 (5.8) 0 10 (7.6) 14 (8.9) Nasopharyngitis 16 (12.3) 10 (9.7) 9 (19.6) 11 (8.3) 24 (15.3) Sinusitis NOS* 17 (13.1) 13 (12.6) 3 (6.5) 7(5.3) 16 (10.2) Upper respiratory tract infection NoS* 8 (6.2) 11 (10.7) 4 (8.7) 6 (4.5) 9(5.7) Investigations Weight increased 5 (3.8) 2 (1.9) 2 (4.3) 0 3 (1.9) Musculoskeletal and connective tissue disorders Arthralgia 11 (8.5) 4 (3.9) 2 (4.3) 5 (3.8) 9 (5.7) Back pain 10 (7.7) 9 (8.7) 4 (8.7) 14 (10.6) 10 (6.4) Neck pain 4 (3.1) 4 (3.9) 0 6 (4.5) 2 (1.3) Pain in limb 10 (7.7) 7(6.8) 2 (4.3) 6 (4.5) 9 (5.7) Nervous system disorders Headache NOS* 35 (26.9) 32 (31.1) 23 (50.0) 34 (25.8) 37 (23.6) Sinus headache 12 (9.2) 5 (4.9) 5 (10.9) 2 (1.5) 8 (5.1) Psychiatric disorders Anxiety NEC** 5 (3.8) 0 0 2 (1.5) 4 (2.5) Depression 4 (3.1) 7(6.8) 0 4 (3.0) 6 (3.8) Insomnia 6 (4.6) 4 (3.9) 2 (4.3) 2 (1.5) 9(5.7) Reproductive system and breast disorders Breast tenderness 10 (7.7) 8 (7.8) 3 (6.5) 17 (12.9) 0 Dysmenorrhea 0 0 3 (6.5) 0 0 Intermenstrual bleeding 9 (6.9) 6 (5.8) 0 14 (10.6) 7(4.5) Respiratory, thoracic and mediastinal disorders Sinus congestion 4 (3.1) 3 (2.9) 3 (6.5) 6 (4.5) 7(4.5) Vascular disorders Hot flushes NOS* 0 3 (2.9) 0 0 6 (3.8) Hypertension NOS* 0 3 (2.9) 0 0 2 (1.3) † Represents milligrams of estradiol delivered daily by each system *NOS represents not otherwise specified **NEC represents not elsewhere classified ***Application site erythema and application site irritation were observed in 3.2% or less of patients across treatment groups.
During the clinical pharmacology studies with MINIVELLE, 35 percent or less of subjects experienced barely perceptible erythema.
No transdermal systems were removed due to irritation.
Three subjects (2.2 percent) reported mild discomfort while wearing MINIVELLE (N=136).
DRUG INTERACTIONS No drug interaction studies have been conducted for MINIVELLE.
Metabolic Interactions In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4).
Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism.
Inducers of CYP3A4 such as St.
John's wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile.
Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.
Side Effects & Drug Interactions SIDE EFFECTS The following serious adverse reactions are discussed elsewhere in the labeling: Cardiovascular Disorders [see BOXED WARNING, WARNINGS AND PRECAUTIONS] Malignant Neoplasms [see BOXED WARNING, WARNINGS AND PRECAUTIONS] Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Menostar was investigated in a 2-year double blind, placebo-controlled, multicenter study in the United States.
A total of 417 postmenopausal women (208 women on Menostar, 209 on placebo) 60 to 80 years old, with an intact uterus were enrolled in the study.
At 24 months, 189 women remained in the Menostar group and 186 remained in the placebo group.
Adverse events with an incidence of ≥ 5 percent in the Menostar 14 mcg group and greater than those reported in the placebo group are listed in Table 1.
Table 1: Summary of Most Frequently Reported Treatment Emergent Adverse Reactions ( ≥ 5 percent) by Treatment Groups Body System Adverse Reactions Menostar 14 mcg/day (N=208) Placebo (N=209) Body as a Whole 95 (46%) 100 (48%) Abdominal Pain 17 (8%) 17 (8%) Accidental Injury 29 (14%) 23 (11%) Infection 11 (5%) 10 (5%) Pain 26 (13%) 26 (12%) Cardiovascular 20 (10%) 19 (9%) Digestive System 52 (25%) 44 (21%) Constipation 11 (5%) 6 (3%) Dyspepsia 11 (5%) 9 (4%) Metabolic and Nutritional Disorders 25 (12%) 22 (11%) Musculoskeletal System 54 (26%) 51 (24%) Arthralgia 24 (12%) 13 (6%) Arthritis 11 (5%) 15 (7%) Myalgia 10 (5%) 6 (3%) Nervous System 30 (14%) 23 (11%) Dizziness 11 (5%) 6 (3%) Respiratory System 62 (30%) 67 (32%) Bronchitis 12 (6%) 9 (4%) Upper Respiratory Infection 33 (16%) 35 (17%) Skin and Appendages 50 (24%) 54 (26%) Application Site Reaction 18 (9%) 18 (9%) Breast Pain 10 (5%) 8 (4%) Urogenital System 66 (32%) 40 (19%) Cervical Polyps 13 (6%) 4 (2%) Leukorrhea 22 (11%) 3 (1%) Postmarketing Experience The following adverse reactions have been identified during post-approval use of the Climara transdermal system and the Menostar transdermal system.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Genitourinary System Changes in bleeding pattern, pelvic pain Breast Breast cancer, breast pain, breast tenderness Cardiovascular Changes in blood pressure, palpitations, hot flashes Gastrointestinal Vomiting, abdominal pain, abdominal distension, nausea Skin Alopecia, hyperhidrosis, night sweats, urticaria, rash Eyes Visual disturbances, contact lens intolerance Central Nervous System Depression, migraine, paresthesia, dizziness, anxiety, irritability, mood swings, nervousness, insomnia, headache Miscellaneous Edema, fatigue, menopausal symptoms, weight increased, application site reaction, anaphylactic reaction DRUG INTERACTIONS Metabolic Interactions In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4).
Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism.
Inducers of CYP3A4 such as St.
John's wort (hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile.
Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.
Side Effects & Drug Interactions Warnings & Precautions WARNINGS Included as part of the PRECAUTIONS section.
PRECAUTIONS Cardiovascular Disorders An increased risk of stroke and DVT has been reported with estrogen-alone therapy.
An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy.
Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.
Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.
Stroke In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years).
The increase in risk was demonstrated in year 1 and persisted [see Clinical Studies].
Should a stroke occur or be suspected, estrogenalone therapy should be discontinued immediately.
Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).1 In the WHI estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years).
[see Clinical Studies].
The increase in risk was demonstrated after the first year and persisted.1 Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.
Coronary Heart Disease In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo2 [see Clinical Studies].
Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since menopause (8 versus 16 per 10,000 women-years).1 In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of CHD events reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women years).1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see Clinical Studies].
In postmenopausal women with documented heart disease (n = 2,763, average 66.7 years of age), in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit.
During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD.
There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years.
Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open-label extension of HERS, HERS II.
Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall.
Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in the HERS, HERS II, and overall.
Venous Thromboembolism In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE), was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women years).
The increase in VTE risk was demonstrated during the first 2 years3 [see Clinical Studies] Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately.
In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years).
Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated.
The increase in VTE risk was demonstrated during the first year and persisted4 [see Clinical Studies].
Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.
If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.
Malignant Neoplasms Endometrial cancer An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in women with a uterus.
The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose.
Most studies show no significant increased risk associated with the use of estrogens for less than 1 year.
The greatest risk appears to be associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more.
This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.
Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important.
Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose.
Adding a progestin to postmenopausal estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.
Breast Cancer The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone.
In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80]5 [see Clinical Studies].
The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg).
After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA.
In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women.
The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo.
Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo.
Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo.
In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group.
Metastatic disease was rare, with no apparent difference between the two groups.
Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups6 [see Clinical Studies].
Consistent with the WHI clinical trial, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use.
The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping).
Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy.
However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.
The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation.
All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations.
In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.
Ovarian Cancer The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer.
After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI, 0.77-3.24).
The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.7 In some epidemiologic studies, the use of estrogen plus progestin and estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer.
However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies, and some report no association.
Probable Dementia In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo.
After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia.
The relative risk of probable dementia for CEalone versus placebo was 1.49 (95 percent CI, 0.83-2.66).
The absolute risk of probable dementia for CEalone versus placebo was 37 versus 25 cases per 10,000 women-years8 [see Use In Specific Populations, and Clinical Studies].
In the WHIMS estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo.
After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia.
The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48).
The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years8 [see Use In Specific Populations, and Clinical Studies].
When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60).
Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see Use in Specific Populations, and Clinical Studies].
Gallbladder Disease A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.
Hypercalcemia Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases.
If hypercalcemia occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.
Visual Abnormalities Retinal vascular thrombosis has been reported in patients receiving estrogens.
Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine.
If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued.
Addition of a Progestin When a Woman Has Not Had a Hysterectomy Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone.
Endometrial hyperplasia may be a precursor to endometrial cancer.
There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens.
These include an increased risk of breast cancer.
Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens.
In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen.
Hypertriglyceridemia In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis.
Consider discontinuation of treatment if pancreatitis occurs.
Hepatic Impairment and/or Past History of Cholestatic Jaundice Estrogens may be poorly metabolized in patients with impaired liver function.
For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued.
Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.
Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range.
Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy.
These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.
Fluid Retention Estrogens may cause some degree of fluid retention.
Women with conditions that might be influenced by this factor, such as cardiac or renal dysfunction, warrant careful observation when estrogen is prescribed.
Hypocalcemia Estrogen therapy should be used with caution in women with hypoparathyroidism as estrogen-induced hypocalcemia may occur.
Exacerbation of Endometriosis A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy.
For women known to have residual endometriosis post-hysterectomy, the addition of progestin should be considered.
Hereditary Angioedema Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.
Exacerbation of Other Conditions Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraines, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.
Laboratory Tests Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms.
Drug-Laboratory Test Interactions Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex; and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III; decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
Increased TBG leading to increased circulating total thyroid hormone levels, as measured by proteinbound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.
T3 resin uptake is decreased, reflecting the elevated TBG.
Free T4 and free T3 concentrations are unaltered.
Women on thyroid replacement therapy may require higher doses of thyroid hormone.
Other binding proteins may be elevated in serum, for example, corticosteroid-binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.
Free hormone concentrations, such as testosterone and estradiol, may be decreased.
Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
Increased plasma high-density lipoprotein (HDL) and HDL2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, increased triglycerides levels.
Impaired glucose tolerance.
Patient Counseling Information See FDA-approved patient labeling (Patient Information and Instructions for Use) Vaginal Bleeding Inform postmenopausal women of the importance of reporting unusual vaginal bleeding to their healthcare providers as soon as possible [see WARNINGS AND PRECAUTIONS].
Possible Serious Adverse Reactions with Estrogen-Alone Therapy Inform postmenopausal women of possible serious adverse reactions of estrogen-alone therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia.
[see WARNINGS AND PRECAUTIONS].
Possible Less Serious but Common Adverse Reactions with Estrogen-Alone Therapy Inform postmenopausal women of possible less serious but common adverse reactions of estrogen-alone therapy such as headache, breast pain and tenderness, nausea and vomiting.
Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term, continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.
Use In Specific Populations Pregnancy MINIVELLE should not be used during pregnancy.
[see CONTRAINDICATIONS].
There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.
Nursing Mothers MINIVELLE should not be used during lactation.
Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk.
Detectable amounts of estrogens have been identified in the breast milk of women receiving estrogen therapy.
Caution should be exercised when MINIVELLE is administered to a nursing woman.
Pediatric Use MINIVELLE is not indicated in children.
Clinical studies have not been conducted in the pediatric population.
Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing MINIVELLE to determine whether those over 65 years of age differ from younger subjects in their response to MINIVELLE.
The Women's Health Initiative Studies In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies].
In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies].
The Women's Health Initiative Memory Study In the WHIMS, ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
Renal Impairment The effect of renal impairment on the pharmacokinetics of MINIVELLE has not been studied.
Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of MINIVELLE has not been studied.
REFERENCES 1.
Rossouw JE, et al.
Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause.
JAMA.
2007;297:1465-1477.
2.
Hsia J, et al.
Conjugated Equine Estrogens and Coronary Heart Disease.
Arch Int Med.
2006;166:357–365.
3.
Curb JD, et al.
Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus.
Arch Int Med.
2006; 166:772-780.
4.
Cushman M, et al.
Estrogen Plus Progestin and Risk of Venous Thrombosis.
JAMA.
2004;292:1573-1580.
5.
Stefanick ML, et al.
Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women with Hysterectomy.
JAMA.
2006;295:1647-1657.
6.
Chlebowski RT, et al.
Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women.
JAMA.
2003;289:3234-3253.
7.
Anderson GL, et al.
Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures.
JAMA.
2003;290:1739-1748.
8.
Shumaker SA, et al.
Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women.
JAMA.
2004;291:2947-2958.
Warnings & Precautions WARNINGS Included as part of the PRECAUTIONS section.
PRECAUTIONS Cardiovascular Disorders An increased risk of stroke and DVT has been reported with estrogen-alone therapy.
An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy.
Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.
Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.
Stroke In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years).
The increase in risk was demonstrated in year 1 and persisted [see Clinical Studies].
Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately.
Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).
In the WHI estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women years) [see Clinical Studies].
The increase in risk was demonstrated after the first year and persisted.
Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.
Coronary Heart Disease In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo2 [see Clinical Studies].
Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since menopause (8 versus 16 per 10,000 women-years).1 In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of CHD events reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).1 An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see Clinical Studies].
In postmenopausal women with documented heart disease (n = 2,763), average age 66.7 years, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit.
During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease.
There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years.
A total of 2,321 women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II.
Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall.
Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall.
Venous Thromboembolism In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE) was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).
The increase in VTE risk was demonstrated during the first 2 years3 [see Clinical Studies].
Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately.
In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years).
Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated.
The increase in VTE risk was demonstrated during the first year and persisted4 [see Clinical Studies].
Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.
If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.
Malignant Neoplasms Endometrial Cancer An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus.
The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose.
Most studies show no significant increased risk associated with use of estrogens for less than 1 year.
The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more.
This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.
Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important.
Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose.
Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.
Breast Cancer The most important randomized clinical trial providing information about breast cancer in estrogenalone users is the WHI substudy of daily CE (0.625 mg)-alone.
In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80]5 [see Clinical Studies].
The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg).
After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA.
In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women.
The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo [see Clinical Studies].
Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE plus MPA compared with placebo.
Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo.
In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group.
Metastatic disease was rare, with no apparent difference between the two groups.
Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups6 [see Clinical Studies].
Consistent with the WHI clinical trial, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use.
The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping).
Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy.
However, these studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.
The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation.
All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations.
In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.
Ovarian Cancer The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer.
After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI, 0.77-3.24).
The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.7 In some epidemiological studies, the use of estrogen plus progestin and estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer.
However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies, and some report no association.
Probable Dementia In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age were randomized to daily CE (0.625 mg)-alone or placebo.
After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia.
The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66).
The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years [see Use in Specific Populations, and Clinical Studies].
In the WHIMS estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo.
After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia.The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48).
The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years8 [see Use in Specific Populations, and Clinical Studies].
When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95 percent CI, 1.19-2.60).
Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see Use in Specific Populations, and Clinical Studies].
Gallbladder Disease A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.
Hypercalcemia Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases.
If hypercalcemia occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.
Visual Abnormalities Retinal vascular thrombosis has been reported in women receiving estrogens.
Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine.
If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued.
Addition Of A Progestin When A Woman Has Not Had A Hysterectomy Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone.
Endometrial hyperplasia may be a precursor to endometrial cancer.
There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens.
These include an increased risk of breast cancer.
Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens.
In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen.
Hypertriglyceridemia In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis.
Consider discontinuation of treatment if pancreatitis occurs.
Hepatic Impairment And/Or Past History Of Cholestatic Jaundice Estrogens may be poorly metabolized in women with impaired liver function.
For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.
Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.
Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range.
Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy.
These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.
Fluid Retention Estrogens may cause some degree of fluid retention.
Women with conditions that might be influenced by this factor, such as a cardiac or renal impairment, warrant careful observation when estrogen-alone is prescribed.
Hypocalcemia Estrogen therapy should be used with caution in women with hypoparathyroidism as estrogen-induced hypocalcemia may occur.
Exacerbation Of Endometriosis A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy.
For women known to have residual endometriosis post-hysterectomy, the addition of progestin should be considered.
Hereditary Angioedema Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.
Exacerbation Of Other Conditions Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.
Laboratory Tests Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful when the Menostar transdermal system is used for the prevention of postmenopausal osteoporosis.
Drug-Laboratory Test Interactions Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
Increased TBG levels leading to increased circulating total thyroid hormone, as measured by proteinbound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.
T3 resin uptake is decreased, reflecting the elevated TBG.
Free T4 and free T3 concentrations are unaltered.
Women on thyroid replacement therapy may require higher doses of thyroid hormone.
Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.
Free hormone concentrations, such as testosterone and estradiol, may be decreased.
Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-l-antitrypsin, ceruloplasmin).
Increased plasma high-density lipoprotein (HDL) and HDL cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, and increased triglyceride levels.
Impaired glucose tolerance.
Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.
Patient Counseling Information See FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).
Vaginal Bleeding Inform postmenopausal women of the importance of reporting vaginal bleeding to their healthcare provider as soon as possible [see WARNINGS AND PRECAUTIONS].
Possible Serious Adverse Reactions With Estrogen-Alone Therapy Inform postmenopausal women of possible serious adverse reactions of estrogen-alone therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia [see WARNINGS AND PRECAUTIONS].
Possible Less Serious but Common Adverse Reactions With Estrogen-Alone Therapy Inform postmenopausal women of possible less serious but common adverse reactions of estrogenalone therapy such as headache, breast pain and tenderness, nausea and vomiting.
Use In Specific Populations Pregnancy Menostar should not be used during pregnancy [see CONTRAINDICATIONS].
There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as oral contraceptives inadvertently during early pregnancy.
Nursing Mothers Menostar should not be used during lactation.
Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk.
Detectable amounts of estrogens have been identified in the breast milk of women receiving estrogen therapy.
Caution should be exercised when the Menostar transdermal system is administered to a nursing woman.
Pediatric Use Menostar is not indicated in children.
Clinical studies have not been conducted in the pediatric population.
Geriatric Use A total of 417 postmenopausal women 61 to 79 years old, with an intact uterus, participated in the osteoporosis trial.
More than 50 percent of women receiving study drug, were 65 years of age or older.
Efficacy in older ( ≥ 65 years of age) and younger ( < 65 years of age) postmenopausal women in the osteoporosis treatment trial was comparable both at 12 and 24 months.
Safety in older ( ≥ 65 years of age) and younger ( < 65 years of age) postmenopausal women in the osteoporosis treatment trial was also comparable throughout the study.
The Women's Health Initiative Studies In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies].
In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies].
The Women's Health Initiative Memory Study In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women [see WARNINGS AND PRECAUTIONS, and Clinical Studies].
REFERENCES 1.
Rossouw JE, et al.
Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause.
JAMA.
2007;297:1465-1477.
2.
Hsia J, et al.
Conjugated Equine Estrogens and Coronary Heart Disease.
Arch Int Med.
2006;166:357-365.
3.
Curb JD, et al.
Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus.
Arch Int Med.
2006;166:772-780.
4.
Cushman M, et al.
Estrogen Plus Progestin and Risk of Venous Thrombosis.
JAMA.
2004;292:1573-1580.
5.
Stefanick ML, et al.
Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy.
JAMA.
2006;295:1647-1657.
6.
Chlebowski RT, et al.
Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women.
JAMA.
2003;289:3234-3253.
7.
Anderson GL, et al.
Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures.
JAMA.
2003;290:1739-1748.
Warnings & Precautions WARNINGS See BOX WARNING The use of unopposed estrogens in women who have a uterus is associated with an increased risk of endometrial cancer.
Cardiovascular Disorders Estrogen and estrogen/progestin therapies have been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism or VTE).
Should any of these occur or be suspected, estrogens should be discontinued immediately.
Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.
Coronary Heart Disease And Stroke In the Women’s Health Initiative (WHI) study an increased risk of stroke was observed in women receiving CE compared to placebo.
In the CE/MPA substudy of WHI an increased risk of coronary heart disease (CHD) events (defined as non-fatal myocardial infarction and CHD death) was observed in women receiving CE/MPA compared to women receiving placebo (37 vs.
30 per 10,000 women-years).
The increase in risk was observed in Year 1 and persisted.
In the same substudy of WHI, an increased risk of stroke was observed in women receiving CE/MPA compared to women receiving placebo (29 vs.
21 per 10,000 women-years).
The increase in risk was observed after the first year and persisted.
[see CLINICAL PHARMACOLOGY and Clinical Studies].
In postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years) a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/ Progestin Replacement Study; (HERS)) treatment with CE/MPA–0.625 mg/2.5 mg per day demonstrated no cardiovascular benefit.
During an average follow-up of 4.1 years, treatment with CE/MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease.
There were more CHD events in the CE/MPA-treated group than in the placebo group in Year 1, but not during the subsequent years.
Participation in an open label extension of the original HERS trial (HERS II) was agreed to by 2,321 women.
Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall.
Rates of CHD events were comparable among women in the CE/MPA group and the placebo group in HERS, HERS II, and overall.
Large doses of estrogen (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risks of nonfatal myocardial infarction, pulmonary embolism, and thrombophlebitis.
Venous Thromboembolism (VTE) In the Women’s Health Initiative (WHI) study, an increased risk of deep vein thrombosis was observed in women receiving CE compared to placebo.
In the CE/MPA substudy of WHI, a 2-fold greater rate of VTE, including deep venous thrombosis and pulmonary embolism, was observed in women receiving CE/MPA compared to women receiving placebo.
The rate of VTE was 34 per 10,000 women-years in the CE/MPA group compared to 16 per 10,000 women-years in the placebo group.
The increase in VTE risk was observed during the first year and persisted [see CLINICAL PHARMACOLOGY and Clinical Studies].
If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.
Malignant Neoplasms Endometrial Cancer The use of unopposed estrogens in women with intact uteri has been associated with an increased risk of endometrial cancer.
The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12-fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose.
Most studies show no significant increased risk associated with use of estrogens for less than 1 year.
The greatest risk appears associated with prolonged use, with increased risks of 15 to 24-fold for 5 to 10 years or more, and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.
Clinical surveillance of all women taking estrogen/progestin combinations is important.
Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose.
Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.
Breast Cancer The use of estrogens and progestins by postmenopausal women has been reported to increase the risk of breast cancer.
The most important randomized clinical trial providing information about this issue is the WHI substudy of CE/MPA [see CLINICAL PHARMACOLOGY and Clinical Studies].
The results from observational studies are generally consistent with those of the WHI clinical trial and report no significant variation in the risk of breast cancer among different estrogens or progestins, doses, or routes of administration.
The CE/MPA substudy of WHI reported an increased risk of breast cancer in women who took CE/MPA for a mean follow-up of 5.6 years.
Observational studies have also reported an increased risk for estrogen/progestin combination therapy, and a smaller increased risk for estrogen alone therapy, after several years of use.
In the WHI trial and from observational studies, the excess risk increased with duration of use.
From observational studies, the risk appeared to return to baseline in about 5 years after stopping treatment.
In addition, observational studies suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen/progestin combination therapy as compared to estrogen alone therapy.
In the CE/MPA substudy, 26% of the women reported prior use of estrogen alone and/or estrogen/progestin combination hormone therapy.
After a mean follow-up of 5.6 years during the clinical trial, the overall relative risk of invasive breast cancer was 1.24 (95% confidence interval 1.01 -1.54), and the overall absolute risk was 41 vs.
33 cases per 10,000 women-years, for CE/MPA compared with placebo.
Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 vs.
25 cases per 10,000 women-years, for CE/MPA compared with placebo.
Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 vs.
36 cases per 10,000 women-years for CE/MPA compared with placebo.
In the same substudy, invasive breast cancers were larger and diagnosed at a more advanced stage in the CE/MPA group compared with the placebo group.
Metastatic disease was rare with no apparent difference between the two groups.
Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between the groups.
The use of estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation.
All women should receive yearly breast examinations by a healthcare provider and perform monthly self-examinations.
In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.
Dementia In the estrogen plus progestin WHIMS, a population of 4,532 postmenopausal women aged 65 to 79 years was randomized to CE/MPA or placebo.
After an average follow-up of 4 years, 40 women being treated with CE/MPA (1.8%, n = 2,229) and 21 women in the placebo group (0.9%, n = 2,303) received diagnoses of probable dementia.
The relative risk for CE/MPA versus placebo was 2.05 (95% confidence interval 1.21 -3.48), and was similar for women with and without histories of menopausal hormone use before WHIMS.
The absolute risk of probable dementia for CE/MPA versus placebo was 45 vs.
22 cases per 10,000 women-years and the absolute excess risk for CE/MPA was 23 cases per 10,000 women-years.
It is unknown whether these findings apply to younger postmenopausal women [see CLINICAL PHARMACOLOGY and Clinical Studies and PRECAUTIONS, Geriatric Use].
Gallbladder Disease A 2 to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.
Hypercalcemia Estrogen administration may lead to severe hypercalcemia in patients with breast cancer and bone metastases.
If hypercalcemia occurs, use of the drug should be stopped and appropriate measures should be taken to reduce the serum calcium level.
Visual Abnormalities Retinal vascular thrombosis has been reported in patients receiving estrogens.
Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine.
If examination reveals papilledema or retinal vascular lesions, estrogens should be discontinued.
PRECAUTIONS General Addition Of A Progestin When A Woman Has Not Had A Hysterectomy Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone.
Endometrial hyperplasia may be a precursor to endometrial cancer.
There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens.
These include: A possible increased risk of breast cancer Adverse effects on lipoprotein metabolism (e.g., lowering HDL, raising LDL) Impairment of glucose tolerance Elevated Blood Pressure In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens.
In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen.
Blood pressure should be monitored at regular intervals with estrogen use.
Hypertriglyceridemia In patients with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis and other complications.
Impaired Liver Function And Past History Of Cholestatic Jaundice Estrogens may be poorly metabolized in patients with impaired liver function.
For patients with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued.
Hypothyroidism Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.
Patients with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range.
Patients dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy.
These patients should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.
Fluid Retention Because estrogens may cause some degree of fluid retention, conditions which might be influenced by this factor, such as patients with asthma, epilepsy, migraine, and cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.
Ovarian Cancer The CE/MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer.
After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE/MPA vs.
placebo was 1.58 (95% confidence interval 0.77-3.24) but was not statistically significant.
The absolute risk for CE/MPA vs.
placebo was 4.2 vs.
2.7 cases per 10,000 women-years.
A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer.
The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies.
The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs.
greater than 5 years [median of 10 years] of use before the cancer diagnosis).
The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27-1.48) and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products.
The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.
Exacerbation Of Endometriosis Endometriosis may be exacerbated with administration of estrogens.
A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen alone therapy.
For patients known to have residual endometriosis post-hysterectomy, the addition of progestin should be considered.
Hypocalcemia Estrogens should be used with caution in individuals with severe hypocalcemia.
Exacerbation Of Other Conditions Estrogens may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.
Patient Information See text of Patient Information.
Physicians are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe Alora.
Laboratory Tests Estrogen administration should be guided by clinical response at the lowest dose for the treatment of vasomotor symptoms and vulvar and vaginal atrophy.
Laboratory parameters may be useful in guiding dosage for the treatment of hypoestrogenism due to hypogonadism, castration and primary ovarian failure.
Carcinogenesis, Mutagenesis, Impairment Of Fertility Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.
Long-term continuous administration of estrogen, with or without progestin, in women with or without a uterus, has shown an increased risk of endometrial cancer, breast cancer, and ovarian cancer.
[see BOX WARNING and WARNINGS and PRECAUTIONS].
Pregnancy Category X Alora should not be used during pregnancy [see CONTRAINDICATIONS].
Nursing Mothers Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk.
Detectable amounts of estrogens have been identified in the milk of mothers receiving estrogen therapy.
Estrogens are not indicated for the prevention of postpartum breast engorgement.
Caution should be exercised when Alora is administered to a nursing woman.
Pediatric Use Estrogen replacement therapy has been used for the induction of puberty in adolescents with some forms of pubertal delay.
Safety and effectiveness in pediatric patients have not otherwise been established.
Large and repeated doses of estrogen over an extended time period have been shown to accelerate epiphyseal closure, which could result in short adult stature if treatment is initiated before the completion of physiologic puberty in normally developing children.
If estrogen is administered to patients whose bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended during estrogen administration.
Estrogen treatment of prepubertal girls also induces premature breast development and vaginal cornification, and may induce gynecomastia [see INDICATIONS and DOSAGE AND ADMINISTRATION].
Geriatric Use In the Women’s Health Initiative Memory Study, including 4,532 women 65 years of age and older, followed for an average of 4 years, 82% (n = 3,729) were 65 to 74 while 18% (n = 803) were 75 and over.
Most women (80%) had no prior hormone therapy use.
Women treated with conjugated estrogens plus medroxyprogesterone acetate were reported to have a 2-fold increase in the risk of developing probable dementia.
Alzheimer’s disease was the most common classification of probable dementia in both the conjugated estrogens plus medroxyprogesterone acetate group and the placebo group.
Ninety percent of the cases of probable dementia occurred in the 54% of women that were older than 70 [see BOX WARNING and WARNINGS, Dementia].
With respect to efficacy in the approved indications, there have not been sufficient numbers of geriatric patients involved in studies utilizing Alora to determine whether those over 65 years of age differ from younger subjects in their response to Alora.
|
More Medical Conditions
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Medical Conditions Definitions Of The Day
- Aortic Coarctations ‐ Narrowing of the lumen of the aorta, caused by deformity of the…
- Gelada Baboons ‐ A genus of Old World monkeys of the subfamily CERCOPITHECINAE,…
- Detections, Signal (Psychology) ‐ Psychophysical technique that permits the estimation of the bias…
- Drug Toxicities ‐ Manifestations of the adverse effects of drugs administered therapeutically…
- Peptide Elongation Factor G ‐ Peptide Elongation Factor G catalyzes the translocation of peptidyl-tRNA…
- Systems, Vasomotor ‐ The neural systems which act on vascular smooth muscle to control…
- Platelet Activating Factor ‐ A phospholipid derivative formed by platelets, basophils, neutrophils,…
- Sialuria, Infantile Form ‐ Autosomal recessive neurodegenerative disorders caused by lysosomal…
- Spastic Paraparesis ‐ Mild or moderate loss of motor function accompanied by SPASTICITY…
- Cycles, Endometrial ‐ The period of the regularly recurring physiologic changes in…